INNOLAB magazine #15.86

Industry Outlook 2023-25: Chilled, Frozen and Processed CHICKEN INDUSTRY

The Ultimate Destination for the MEAT PROCESSING and Packaging Industry

Probiotic DIETARY SUPPLEMENTS for Digestive System

Importance of Water Activity Towards FOOD SAFETY

Identification of Fifteen Potential BLOCKBUSTER DRUGS

OHUAS Mini Stirrer

OHAUS Indochina Ltd.

Wutti.Techakasembundit@ohaus.com

เครื่องกวนส�รละล�ย Mini Stirrer ของ โอเฮ้�ส์ เครื่องกวนส�รละล�ยขน�ดกะทัดรัด ของโอเฮ้ � ส์ รองรับปริม � ตรสูงสุดที่ 1 ลิตร ที่คว�มเร็วรอบในก�รกวนตั้งแต่ 100 - 1,200 rpm พื้นผิวเป็น Ceramic สีข�ว ขน�ด 4x4 นิ้ว ทนก�รกัดกร่อนของส�ร เคมีและทำ�คว�มสะอ�ดง่�ย ผลิตในประเทศ สหรัฐอเมริก�

Maximum Volume 1 liter, Speed Range 100-1,200 rpm, Ceramic top plate with chemical resistance and easy to clean. It is made in USA.

Incubating Microplate Shaker

OHAUS Indochina Ltd.

OHAUS Dry

Block

เครื่องเขย่�แบบควบคุมอุณหภูมิสำ�หรับใช้ กับไมโครเพลทของโอเฮ้�ส์ ทำ�ง�นด้วยไมโครโพรเซสเซอร์ ควบคุม อุณหภูมิได้ตั้งแต่อุณหภูมิห้อง +5°C ถึง 65°C ที่คว�มเร็วรอบในก�รเขย่�ตั้งแต่ 1001,200 รอบต่อน�ที และตั้งเวล�ในก�รเขย่� ได้ตั้งแต่

1 วิน�ที ถึง 160 ชั่วโมง ส�ม�รถ

Ideal for Incubation and Activation of Cell Cultures เครื่องทำ�คว�มร้อนหลอดทดลองหรือ Dry block heater เป็นอุปกรณ์ที่เหม�ะสม ที่สุดสำ�หรับแอปพลิเคชันที่ต้องก�รอุณหภูมิ คงที่ และระดับคว�มร้อนที่ส�ม�รถทำ�ซ้ำ�ได้ ก�รออกแบบให้หลอดชิดกับช่องทำ�คว�ม ร้อนทำ�ให้ส�ม�รถรักษ�คว�มร้อนได้ดีที่สุด ก�รทำ�คว�มร้อนจึงมีประสิทธิภ�พ เครื่อง ส�ม�รถใช้ง�นได้หล�กหล�ย ได้แก่ ก�ร ศึกษ�โปรตีนที่เสียสภ�พธรรมช�ติ ก�รบ่ม และก�รกระตุ้นเซลล์ที่เพ�ะเลี้ยง ก�รศึกษ� ปฏิกิริย�ของเอนไซม์และก�รวิเคร�ะห์ท�ง อิมมูโน เครื่องส � ม � รถใช้ง � นกับหลอด ขน�ดไมโครปริม�ตร 0.2 มิลลิลิตร ไปจนถึง หลอดปั่นเหวี่ยงปริม�ตร

A New Exhibition

นิทรรศการด้านการแปรรูปเนื้อสัตว์ที่เรียกได้ว่าเป็นงานที่ถอด แบบมาจากงาน IFFA นิทรรศการด้านเนื้อสัตว์และโปรตีนระดับโลก

This is a new exhibition that we would like to introduce to you. It is Meat Pro Asia, meat processing exhibition. It is a sister exhibition of IFFA, the exhibition for global meat and protein industry located in Germany. This year VNU Asia Pacific will hold Meat Pro Asia on March 8-10 at IMPACT Challenger 1, Muang Thong Thani co-located with VIV Asia. Joining Meat Pro Asia encourages you to discover the comprehensive technology, innovation, products, tools&equipment and networking for meat and livestock industry.

Don’t certainly miss the event !

Karuna Chinthanorm Chief Editorial Officer

SOMKID RUENPARKWOOT somkid-doa@hotmail.com

SUPAWAT SUKMARK ss@media-matter.com

KARUNA CHINTHANOM kc@media-matter.com

ชัฏไพศาล APAPAN CHATPAISARN editor@media-matter.com

สิทธิพร ชมภูรัตน์ SITTHIPORN CHOMPURAT journalist@media-matter.com เบญจมาศ ศรีสุข BENJAMAS SRISUK innolab@media-matter.com

จีนถนอม WANASANAN CHINTHANOM innolab@media-matter.com

ทูโด THU DO innolab.vn@media-matter.com

PUBLISHER

43/308

10150

43/308 Moo 1, Jomthong Road, Jomthong, Bangkok 10150 Thailand TaxID 0105552007301

+66 875171651 F +66 2045 5358 innolab@media-matter.com

http://www.innolabmagazine.com innolabmagazine

The publisher endeavors to collect and include complete, correct and current information in INNOLAB but does not warrant that any or all such information is complete, correct or current. The publisher does not assume, and hereby disclaims, and liability to any person or entity for any loss or damage caused by errors or omissions of any kind, whether resulting from negligence, accident or any other cause. INNOLAB does not verify any claims or other information appearing in any of the advertisements contained in the magazine, and cannot take any responsibility for any losses or other damages incurred by readers in reliance on such content.

LARGEST LEADING TRADE FAIR IN VIETNAM

19 - 21 April 2023

Ho Chi Minh City • Vietnam

SECC - Saigon Exhibition and Convention Center

สหราช อาณาจักร (24.6%) เนเธอร์แลนด์ (7.0%)

และเกาหลีใต้ (3.8%)

ไก่แช่แข็ง สัดส่วน 38.8% ตลาดหลัก คือ ญี่ปุ่น (สัดส่วน 40.3% ของปริมาณส่งออก

รองลงมา คือ จีน (29.5%)

มาเลเซีย (13.3%) และเกาหลีใต้ (3.6%)

ไก่แช่เย็น สัดส่วน 0.9% ตลาดส่ง ออกหลักเป็นประเทศเพื่อนบ้าน เช่น เมียนมา (สัดส่วน 64.0% ของปริมาณส่งออกไก่แช่เย็น ทั้งหมด) ลาว (17.2%) ฮ่องกง (14.2%) และ กัมพูชา (4.1%)

สำาหรับแหล่ง เลี้ยงไก่ส่วนใหญ่อยู่ในภาคกลาง (สัดส่วน

71.0% ของปริมาณการผลิตไก่เนื้อทั้งประเทศ)

ภาคตะวันออกเฉียงเหนือ (14.6%) ภาคเหนือ (8.2%) และภาคใต้ (6.2%) ตามลำาดับ หาก

พิจารณารายจังหวัด พบว่ามีการเลี้ยงไก่เนื้อใน จังหวัดลพบุรีมากที่สุด (19.8% ของผลผลิต

(10.6%) ชลบุรี (9.0%) นครราชสีมา (7.7%)

10.8%

1.0 ล้านตัน แรงขับเคลื่อนหลักมาจากการส่งออกไก่แปรรูป ตามอุปสงค์เพื่อความมั่นคงทางอาหารของ ประเทศคู่ค้าสำาคัญ อาทิ ญี่ปุ่นและสหราช อาณาจักร ยังคงเพิ่มขึ้น ขณะที่เกาหลีใต้และ

Figure: The Supply Chain of Thai Chicken Industry (2021)

สหรัฐต่อตัน (+5.4%) แรงหนุนจากการขยาย ตัวของตลาดหลัก ได้แก่ 1)

ปริมาณส่งออกอยู่ที่ 3.1 แสน ตัน (+7.8%) คิดเป็นสัดส่วน 47.6% ของ ปริมาณการส่งออกไก่แปรรูปจากไทยทั้งหมด อานิสงส์จากข้อตกลงการค้าเสรีไทย-ญี่ปุ่น (JTEPA กับ AJCEP) ประกอบกับพฤติกรรม ของผู้บริโภคในญี่ปุ่นที่นิยมบริโภคอาหารพร้อม ทานและ Fast food เพิ่มขึ้นถึง 20-30% 2) สหราชอาณาจักร ปริมาณส่งออกอยู่ที่ 1.7 แสนตัน (+26.5%) คิดเป็นสัดส่วน 26.5% เนื่องจากไข้หวัดนกที่ระบาดในยุโรปส่งผลต่อ อุปทานไก่ในประเทศ รวมถึงต้นทุนการผลิต ที่เพิ่มขึ้นตามราคาวัตถุดิบและพลังงาน หนุน การนำาเข้าไก่แปรรูปจากไทยซึ่งมีต้นทุนต่ำากว่า 3) เนเธอร์แลนด์ ปริมาณส่งออกอยู่ที่ 0.5 แสนตัน (+45.3%) คิดเป็นสัดส่วน 8.6% เนื่องจากผลผลิตไก่เนื้อในประเทศได้รับความ เสียหายจากการระบาดของไข้หวัดนก

ชายแดนไทย-เมียนมา

2) ฮ่องกง ปริมาณส่งออกอยู่ที่ 1.1 พันตัน (-8.6%) คิดเป็นสัดส่วน 21.5% ผลมาจาก การเข้มงวดในความปลอดภัยด้านอาหารใน ช่วง COVID-19

3) สิงคโปร์ ส่งออกอยู่ที่ 365 ตัน (+2,802.4%) คิดเป็นสัดส่วน 7.0% แรงหนุน มาจากความต้องการเพื่อชดเชยการนำาเข้าไก่ จากมาเลเซียที่ลดลงจากปัญหาการขาดแคลน แรงงานการผลิตในมาเลเซีย

ความต้องการในประเทศ: คาดการณ์ที่ 1.88 ล้านตัน ขยายตัว 0.9% ตามการทยอย ฟื้นตัวของกิจกรรมทางเศรษฐกิจ

สะท้อนว่าไทยมีความได้เปรียบประเทศคู่แข่งในการส่งออกไก่แปรรูปและไก่แช่แข็งพิจารณาจากค่าดัชนี

Output Thailand’s chicken products is forecasted to expand by an average of 2.5-3.5% annually over 2023 to 2025. Within Thailand, the full reopening of the country is underpinning an accelerating rebound in tourist arrivals. This, coupled with broader recovery in the economy, will support stronger demand for chicken from restaurants and food processors. Exporters of chicken products can also look forward to an improving business environment thanks to: (i) greater sales into major overseas markets, including Japan and the UK, thanks to the effect on demand from food security; (ii) increasing penetration of new markets in the Middle East, especially in Saudi Arabia, where trade connections are deepening; and (iii) the widespread recognition of Thai chicken’s high production standards and the impact on sales of free trade agreements signed between Thailand and major trade partners. Nevertheless, despite this broadly positive outlook, the impact of a sustained rise in inflation on the cost of living will mean that global economic growth will likely drag through 2023, and this will then affect exports. In addition, the higher cost of inputs, most obviously of animal feed, will also weigh on the industry.

Krungsri Research view

Over 2023-2025, demand for processed, chilled, and frozen chicken will strengthen on both domestic and international markets. Growth in downstream industries will generate benefits along the length of chicken supply chains, though will be especially noticeable for chicken farms. However, rising production costs may weigh on profits, with this likely to be a particular problem for smaller players.

 Producers of frozen and processed chicken: Income growth will be supported by stronger exports and the benefits Thailand gains from the widespread acceptance of its production processes, recognition of which is gaining ground in export markets. Players will thus be able to both develop existing major markets and extend into high-potential new areas, most notably in Saudi Arabia, which is opening up as trade relations deepen. The prediction is therefore that exports of frozen and processed chicken will rise by 2.0-4.0% and 1.5-3.0% respectively, although weakness in the global economy and the high cost of animal feed will drag on growth in 2023.

 Chicken farms: Improving economic activities at home and abroad will support greater demand for chicken products, especially for large operations that are able to benefit from their economies of scale, effective cost control and wellestablished markets, or for players that are embedded in supply chains operated by producers of frozen and processed chicken goods. However, while these players will gain from more vibrant export markets, small independent operations that are dependent on the domestic market will face greater difficulties due to their lower production standards and their restricted access to markets. The industry is also marked by the large number of suppliers active in the market, and so competition is intense. In this situation, rising operating costs will likely impact profitability, especially for smaller operations.

OVERVIEW

Chicken meat has the advantage of being a protein-rich, low-fat commercially-farmed animal, and because modern breeds grow to maturity very rapidly, chicken flocks return profits over a relatively short

time-span compared to other meat products. As a commercial undertaking, raising chickens also benefits from the animal’s high conversion rate and resistance to disease, and the result of this is that chicken is farmed and consumed in greater quantities than any other animal; per capita global consumption averages 14.8 kilograms/person/year, compared to 11.1 kilograms for pork and 6.3 kilograms for beef (data correct as of 2021). The majority of the consumable output of the chicken industry is distributed in the form of (i) chilled chicken products, (ii) frozen chicken products, and (iii) processed chicken (chicken that is cooked or flavored and then frozen). Each of these product groups involves a different type of processing.

Chilled Chicken: Chilled chicken products include whole chickens, filleted chicken meat and offal, and other parts of the body, which are preserved at a temperature of 0-5 degrees Celsius.

Frozen Chicken: Frozen chicken products include whole chickens, filleted chicken meat and offal, and diced and minced chicken meat, which is stored at temperatures below -18 degrees Celsius.

Processed Chicken: These are downstream products that provide manufacturers with the opportunity to generate added value. Processed chicken products can be split into two main classes: (i) uncooked processed chicken, which consumers will then prepare themselves, and (ii) semi- or fully-cooked chicken products that are frozen at temperatures below -18 degrees Celsius. This includes grilled chicken legs, smoked chicken wings, chicken satay, chicken burgers, chicken nuggets, chicken steaks, chicken karaage, chicken meatballs, battered and fried chicken, and marinated chicken.

Global output of chicken meat rose 1.3% YoY to 100.5 million tonnes in 2021. The Americas is the world’s primary source of chicken, accounting for 46.9% of global production, followed by Asia (33.8% of output), Europe (14.7%), Africa (3.2%) and Oceania (1.3%). In terms of individual markets, the USA sits in first place, producing 20.4 million tonnes of chicken per year (20.3% of all global output), followed by China with 14.7 million tonnes (14.6%), Brazil with 14.5 million tonnes (14.4%), and the European Union with 10.9 million tonnes (10.8%). Thailand’s annual production of chicken meat comes to 3.2 million tonnes, which gives it a 3.2% share of world output and places the country in 7th position globally (source: USDA). In terms of consumption, the overwhelming majority of output is absorbed by domestic markets (an average of 97.6% globally). Thus, the biggest buyers of chicken are US consumers, which with a market sized at 17.2 million tonnes, accounts for 17.5% of global demand, followed by China (15.0 million tonnes, or 15.3% of the

global market), Brazil (10.3 million tonnes, or 10.5%), and the EU (9.7 million tonnes, or 9.9%).

Worldwide, chicken exports total 18.2 million tonnes, which in 2021 generated annual receipts of USD 35.3 billion. With a 24.6% share of this market, Brazil is the world’s most important exporter of chicken products, followed by the US (20.5% of the market), Poland (9.7%), the Netherlands (7.8%), and Thailand (5.4%). Details of exports of the different product groups are given below:

Frozen Chicken: By volume and value, this accounts for respectively 68.9% and 54.5% of global chicken exports. Within this category, by value, 85.8% of all exports are of filleted chicken products, with the remainder being of whole chickens. The world’s three biggest exporters of frozen chicken products are Brazil, the US, and the Netherlands, which together have a greater than 64% market share. By comparison, Thailand has just a 3.4% slice of the market, putting the country in 6th place in the global rankings.

 Processed Chicken: While by volume, only 11.6% of global exports are of processed chicken, the share jumps to 23.8% when considered by value. Within this segment, Thailand is the world’s biggest exporter, enjoying a 26.0%

market share by volume, followed by China (12.7%), Germany (8.2%), and Poland (8.0%).

Chilled Chicken: Considered by value and volume, respectively 21.7% and 19.5% of global exports of chicken products are of chilled chicken. Of this total, 85.0% (by volume) are of filleted products, the remainder being of whole chickens. With a 20.3% market share (by volume), the US is the world’s biggest exporter, followed by the Netherlands (17.1%) and Poland (16.6%). Thailand’s presence in this market is very slight, the country sitting in 25th place in the world rankings with just a 0.2% market share.

However, the leading importers of chicken products are somewhat diverse

Frozen chicken: This accounts for 71.1% of global demand for chicken by volume. The most important markets are China (12.5% of all imports of frozen chicken worldwide), Japan (5.1%), the UAE (4.1%), and Saudi Arabia (3.7%).

Chilled chicken: This segment represents 17.4% of chicken imports worldwide, though importers generally buy from within their own region. Within Europe, the biggest importers are the Netherlands (15.8% of global

imports of chilled chicken), Germany (12.4%), France (9.6%), and Belgium (6.7%). In North America, Mexico absorbs 21.7% of global exports and Canada another 3.7%, with these products originating largely in the US.

Processed chicken: This accounts for the remaining 11.5% of global chicken imports. The world’s biggest importers are Japan (25.4% by volume of all imports of processed chicken), the United Kingdom (16.4%), the Netherlands (7.5%), Germany (5.9%), and France (4.5%).

Thai output of chicken products totaled 2.8 million tonnes in 2021, of which 66%, or 1.9 million tonnes, was consumed by the domestic market, with Thai consumers typically buying fresh filleted products. The remainder of national output was then processed into chilled and frozen chicken products, mostly for export; by value, Thailand is the world’s biggest exporter of processed chicken and its 6th biggest exporter of frozen chicken (source: Trademap, 2021).

The export market has undergone significant changes since 2004, when Thailand was affected by a major outbreak of Highly Pathogenic Avian Influenza (HPAI). As a result of concerns over possible infection and thus of the safety of raw chicken originating in Thailand, imports by Japan, Germany, South Korea, and China (a combined 79.5% of exports by volume) were halted. In response to this, Thai producers overhauled their operations and placed a much greater emphasis on the production and output of processed chicken, which was still accepted in Thailand’s export markets. This then led to the establishment of processed chicken as the sector’s primary product, and

so processed chicken now accounts for 60.3% of all Thai chicken exports volume. Thus, as of 2021, Thailand had a 26.0% share of the global market for processed chicken goods. The situation for exports of frozen chicken returned to a more positive state after 2011 with the abating of the HPAI outbreak. In addition, the development of evaporative aircooling systems (EVAPs) for use on Thai chicken farms also helped to cut infection rates, in particular in flocks managed by the major players and on contract farms. The introduction of the World Organisation for Animal Health’s compartment system was another important factor helping to support the industry, and as such, despite periodic outbreaks elsewhere, no cases of HPAI have been reported in Thailand since 2007. This then helped to significantly boost exports of frozen chicken to the EU from 2012, and from 2014, to Japan too, though sales to the latter were helped further by the signing of the JTEPA agreement.

As such, export volume of Thai frozen chicken products surged by an annual average of 29.2% over the period 2011-2021, and this then helped Thailand expand its global market share to 3.4% and to lift the country into 6th place in the world ranking of exporters (up from a 0.5% share of the global market and 17th place in 2011). This rapid expansion was helped by: (i) the lifting of restrictions on the import of frozen chicken by Thailand’s trade partners; and (ii) outbreaks of chicken flu in other exporting nations, including the US, and EU. Export volume of processed chicken products also rose through this period, though this was at the lower average rate of 3.2% per year over 2011-2021. Overseas sales have been boosted by confidence in the safety of closed EVAP-style farms operated by the major Thai players, and at present, the most important markets for Thai exports of processed chicken are Japan, the ASEAN region, and the EU. Sales have also been helped by the exit of the UK from the EU and

Figure: World Chicken Exports (2021)

the resulting changes to quotas for imports of chicken products from Thailand; these now stand at 0.19 million tonnes for imports to the EU and 0.13 million tonnes for those to the UK, giving a total allowance of 0.32 million tonnes, compared to the earlier pre-Brexit quota of 0.27 million tonnes.

By volume, Thai exports of chicken products are split between 60% processed, 39% frozen, and 1% chilled chicken (data correct as of 2021). The main export markets are Japan, which buys mostly processed and frozen chicken, and the EU, which imports processed chicken. Thailand’s main competitor is Brazil, the world’s biggest exporter of frozen chicken. Details for individual product categories are given below:

Processed chicken: This accounts for 60.3% of all exports of chicken products from Thailand. The main markets are Japan (52.4% of all exports of processed chicken), the UK (24.6%), the Netherlands (7.0%), and South Korea (3.8%).

 Frozen chicken: 38.8% of chicken exports are of frozen goods, and these go to Japan (40.3% of all exports of frozen chicken products), China (29.5%), Malaysia (13.3%), and South Korea (3.6%).

Chilled chicken: Only 0.9% of Thai chicken exports are of chilled chicken products, and the main markets are all bordering or near to Thailand. Thus, Myanmar takes 64.0% of exports of these, followed in importance by Laos PDR (17.2%), Hong Kong (14.2%), and Cambodia (4.1%).

The large players in the industry, which are the source of around 90% of all chicken produced in Thailand, typically invest in operations across

the length of the supply chain, from upstream production of animal feed, through chicken raising (both via their own, directly-managed operations and via independent farmers that operate under contract farming arrangements) to slaughterhouses and downstream food processing plants that operate according to recognized standards. This then gives large players advantages with regard to their more efficient cost control and their greater economies of scale. Small operations account for the remaining 10% of production, with these players almost entirely dependent on the domestic market. In terms of the geographical distribution of flocks, these are overwhelmingly found in the central region (the source of 71.0% of all chicken produced in Thailand), followed by the northeast (14.6%), the north (8.2%) and the south (6.2%), while by individual province, Lopburi is the most productive (19.8% of all national chicken output), followed by Kanchanaburi (10.6%), Chonburi (9.0%), Nakhon Ratchasima (7.7%), and Prachinburi (6.7%)

Thai operations benefit from the skill of the local workforce, their access to manufacturing technology, their use of modern production techniques, their ability to develop products that meet market demand, the high standards of their farms, and their success in controlling and preventing outbreaks of disease. Beyond this, the fact that Thailand has agreed FTAs with many of its trade partners has also helped to strengthen the competitiveness of Thai operations and widened the spread of markets for Thai chicken products..

SITUATION

In 2022 total Domestic output of Thailand’s chicken production is 1.8 billion head (up 1.0%) and generated 2.89 million tons of meat (up 3.3%), helped by stronger demand and elevated fears over food security that were triggered by the outbreak of the Ukraine war. At the same time, supply to global markets was affected by outbreaks of Highly Pathogenic Avian Influenza (HPAI) in many countries, and so overall Thai exports of chicken products jumped 10.8% to 1.0 million tonnes, largely due to stronger sales of processed chicken. Overseas sales of processed chicken have benefited from worries over food security in the major markets of Japan and the UK, and from growing Chinese and South Korean acceptance of Thai production standards. The combination of rising demand and weakening supply naturally fed into higher prices, and so average export prices climbed 12.4% in the period. This then helped to boost receipts from chicken exports by 24.7% to a total of USD 4.1 billion. The situation for different product categories is given below.

 Processed chicken: In 2022, exports jumped 18.5% to 650,000 tonnes, which then generated receipts of USD 2.9 billion (up 24.8%). Average export prices rose 5.4% to 4,497 USD/tonne on stronger demand in some of the main overseas markets.

1) Japan: The Japanese market absorbed 310,000 tonnes of processed chicken (up 7.8%), or 47.6% of all Thai exports. Sales have benefited from JTEPA and AJCEP free-trade agreements, as well as from the 2030% increase in demand for fast food and ready-to-eat meals in Japan.

2) The United Kingdom: Exports climbed 26.5% to 170,000 tonnes, or

26.5% of total exports of processed chicken, boosted by HPAI outbreaks in Europe that impacted local supply of chicken. Moreover, increasing cost of raw materials and energy put upward pressure on production cost in UK. This support demand for relatively cheaper imports of processed chicken from Thailand.

3) The Netherlands: Exports surged 45.3% to 56,000 tonnes, 8.6% of total overseas sales. The Dutch market was affected by a domestic outbreak of HPAI, which then caused a sharp spike in imports from Thailand to replace lost local supply.

Frozen chicken: Export volume remained unchanged from 2022 at 350,000 tonnes, but prices climbed 23.8% to 3,159 USD/tonne, which then helped to lift the total export receipts to grow 25.4% to USD 1,130.8 million. The major markets are:

1) Japan: Sales into the Japanese market slipped -5.0% to 140,000 tonnes, though this still accounted for 38.4% of all exports of Thai frozen chicken. This decline contrasts with the strengthening of demand seen for processed chicken, reflecting the shift of customer preference towards cooked and ready-to-eat chicken during the COVID-19 pandemic.

2) China: Exports slumped -18.2% to 90,000 tonnes in the period (24.1% of all exports). This decline was triggered by the introduction of strict food safety standards in China during the Covid-19 pandemic (the GACC regulations) that caused some Thai processing plants to temporarily halt exports to China as they worked to meet these requirements.

3) Malaysia: Exports climbed 54.3% to 70,000 tonnes, or 20.5% of the segment. Migrant laborers working in the Malaysian food-processing industry returned home enmasse

during the pandemic, but many have failed to come back to Malaysia. The resulting labor shortages have meant that domestic supply has been insufficient to meet demand, with Thai imports filling the gap.

Chilled chicken: Exports crashed to 5,300 tonnes (down -39.5%), though a 29.1% increase in average prices to 2,476 USD/tonne kept the decline in overall income to a drop of -20.9% YoY. Receipts thus totaled USD 12.8 million.

1) Myanmar: Exports dropped -42.4% to just 3,200 tonnes (61.0% of all exports of chilled chicken) as a result of the impact of the country’s deep economic and political woes on consumer spending power. Exports were further hurt by the closure of border crossings between Thailand and Myanmar.

2) Hong Kong: Stricter food safety standards during COVID-19 pulled imports from Thailand down by -8.6% to 1,130 tonnes, 21.5% of exports within the segment.

3) Singapore: Exports exploded in the period, rising 2,802.4% to 365 tonnes (7.0% of the total) thanks to labor shortages in Malaysia that diverted demand to Thailand.

 Domestic demand: This is estimated to have expanded 0.9% to 1.88 million tonnes. The market has benefited from the lifting of pandemic restrictions, which then supported recovery in the restaurant and tourism industries, and boosted economic activity generally.

 Farmgate prices: The average price is THB 44.0/kilogram, up from THB 34.9/kilogram in 2021 because the higher cost of animal feed, energy, and labor. Prices have also been pushed up by the effects of African swine fever on the supply of pork and the resulting diversion

of demand from pork to chicken. Therefore, domestic farmgate prices are expected to remain at a high level.

Export prices of chicken products: The export prices in the world market and of Thailand will continue to rise due to the higher cost of energy and animal feed, together with rising inflation. During 10M2022, the average export prices of frozen chicken from the main exporters such as Brazil and Netherlands rose by 23.4% YoY and 21.1% YoY respectively. Meanwhile, Thailand’s export prices increased 25.1% YoY. In addition, the average export prices of 6M2022 processed chicken in China and Germany rose 3.5% YoY and 0.9% YoY respectively, while Thailand’s export prices increased 1.2% YoY

OUTLOOK

Over 2023-2025, global chicken yields will rise at an average annual rate of 4.0-5.0%, while Thai output of processed, chilled, and frozen chicken should expand by 2.5-3.5 per year. The latter will be boosted by stronger domestic demand and by growth in export markets, in particular in: (i) Japan, where economic activity should recover; (ii) China, where restrictions on imports from Thailand will be relaxed; (iii) EU and the UK, where import quota allowances will be raised; and (iv) new markets such as Saudi Arabia, where trade relations have recently been resumed, as well as other GCC nations. Details are given below.

 Domestic chicken yields: These should rise by 2.5-3.5% annually to a total of 1.87-1.99 billion head, or 2.99-3.18 million tonnes of meat. Production will be lifted by the incentive effect of stronger prices that are forecast to run in the range of THB 44.0-45.0 /kilogram on

continuing worries over food security

Domestic demand: Consumption is expected to strengthen by 3.04.0% per year on steady economic recovery now that the country has fully reopened. In particular, demand will be driven by the rebound in the tourism, hotel, and restaurant industries.

 Exports: Overseas sales will expand by 2.5-3.5% annually. Through 2023, growth will be restrained by sluggishness in the global economy, but the situation should improve in 2024 and 2025, and growth in exports will accelerate thanks to the following factors:

- Global consumption of chicken products is forecast to strengthen by 1.5% annually, bringing total demand from 135 million tonnes in 2022 to 137-142 million tonnes over 20232025. Growth will partly be driven by rising consumer worries over personal health, which is shifting demand from high-fat red meats such as pork and beef to lower-fat chicken. Chicken is also a favored staple in low- and middle-income countries.

- Periodic outbreaks of Highly Pathogenic Avian Influenza (HPAI) and African swine fever (ASF) will affect production in affected countries (China, Brazil, Europe, and the US) over an extended timeframe. For example, it took more than three years for China and Vietnam to recover from the spread of ASF in domestic herds and for yields to return to their pre-outbreak level. By contrast, Thai chicken production meets recognized international standards, and Thai chicken meat is free from contamination with human pathogens (e.g., Covid-19) or animal illnesses (e.g., HPAI). Thai products are thus broadly accepted for their

high quality, and this will help to lift demand further.

- The competitiveness of Thai chicken products will be boosted by both free-trade agreements that have already been concluded and by those that are under discussion (e.g., with Turkey, Pakistan, and Sri Lanka). This process has been accelerated by the establishment in June 2021 of the Joint Economic and Trade Committee (JETCO) that marked the beginning of preparations for negotiations over an FTA with the United Kingdom. This should then lead to an increase in exports to the UK beyond those already gained by the post-Brexit expansion in the quota allowance for imports of Thai chicken to EU, from 268,743 to 315,541 tonnes per year.

- New markets in the Middle East and Asia will include: (i) Saudi Arabia, which is increasingly recognizing Thai adherence to halal standards, especially in the market for frozen chicken; (ii) China, where following their temporary suspension in June 2021, Thai poultry slaughterhouses and processing plants producing frozen chicken products have been granted permission to operate; and (iii) South Korea, which has granted permission to an additional 7 Thai processors to export to the country.

The various influences on the market described above will help to underpin growth in exports of the main chicken product groups over the next three years. Due to the competitiveness of Thai players, in

particular in the European market, processed chicken will remain the most important segment. Now that the country is rapidly moving away from its zero-Covid policy, exports of frozen chicken will benefit from recovery in the Chinese market, as well as from strengthening demand in Saudi Arabia, whereas for overseas sales of chilled chicken, growth will be dependent on rising regional consumer spending power. Krungsri Research thus sees export volume of processed chicken increasing by 1.5-3.0% annually over 20232025, while for chilled and frozen products, annual growth should average 2.0-4.0%.

Nevertheless, Thai producers may have to contend with higher production costs stemming from more expensive inputs. This will likely extend to include the soy meal and corn used as an animal feed. Supplies of these sourced from within Thailand are likely to be insufficient to meet demand and so chicken farmers will have to turn to imports, although the additional costs entailed by this will then place Thai producers at a competitive disadvantage relative to players in Brazil and the US, which will continue to be supplied by their domestic markets. 

Understanding the Importance of Water Activity Towards Food Safety

มีการวัดที่สำาคัญสองประการที่ผู้ผลิตอาหารทุกรายต้องคำานึง ถึง คือ ปริมาณความชื้นและวอเตอร์แอคทีวิตี แม้ว่าการวัดเหล่านี้อาจฟังดูคล้ายกัน

ใช้เครื่องวัดค่าวอเตอร์แอคทีวิตี จำานวน ตัวอย่างที่ต้องการจะถูกใส่ลงในภาชนะเก็บ ตัวอย่างค่าวอเตอร์แอคทีวิตีและถูกนำาไปที่ อุณหภูมิแวดล้อมจากนั้นวางตัวอย่างไว้ภายในเซลล์วัดค่า สุญญากาศของมาตรวัดค่าวอเตอร์แอคทีวิ ตีที่สอบเทียบแล้ว เมื่อบรรยากาศภายใน เซลล์มีความสมดุล และการอ่านข้อมูล ดิจิทัลมีความเสถียร ก็สามารถบันทึกค่า วอเตอร์แอคทีวิตีได้ การควบคุมอุณหภูมิอย่างแม่นยำาเป็น สิ่งสำาคัญมากขณะทำาการวัดค่า ควรสอบ เทียบอุปกรณ์ที่อุณหภูมิเดียวกันกับที่ใช้ใน การวิเคราะห์ตัวอย่าง และตัวอย่างที่จะวัด ควรจะเหมือนกัน 

โดยที่ค่าวอเตอร์แอคที

วิตี (aw) เป็นอัตราส่วนของความดันไอ ของน้ำาในอาหาร (P) ต่อความดันไอของ

(P0) ที่อุณหภูมิและความดัน

When it comes to food safety and quality, there are two critical measurements that all food manufacturers must be concerned with: moisture content and water activity. While these measurements may sound similar, they are not the same; nor are they interchangeable. Moisture content and water activity are measured for two different purposes. Each test reveals its own insights about the yield, quality, and safety of your foods.

Difference Between Moisture Content and Water Activity

Moisture content is a measurement of the total amount of water contained in a food, usually expressed as a percentage of the total weight. It is used for determining the dry weight of your food and ingredients, as well as to calculate the total yield. It can also be used to confirm whether the drying process of food is completed. Meanwhile, water activity (aw) is a measurement of the availability of water for biological reactions. It determines the ability of microorganisms to grow. It is primarily used to determine the necessary food storage requirements and shelf life of your products.

Closer Look at Water Activity

The higher the water activity, the faster microorganisms like bacteria, yeast, and mold will be able to grow. This results in higher standards of food storage.

aw= P/P0 where aw is expressed as the ratio of the vapor pressure of food (P) to the vapor pressure of pure water (P0) under those same conditions. It predicts whether water is likely to move from the food product into the cells of micro-organisms that may be present.

The water activity is a value between 0 and 1. A value of 0 means there is absolutely no available water, which is very rare in food products. A value of 1 means all water in the product is available, which is pure water. Most foods hover within a range of 0.2 and 0.99 for water activity.

Importance in Food Safety

Microorganisms have a limiting water activity level below which they will not grow. Water activity, not water content, determines the lower limit of available water for microbial growth. The lowest aw at which most food spoilage bacteria will grow is about 0.90.

Staphylococcus aureus under anaerobic conditions is inhibited at an aw of 0.91, but aerobically the aw level is 0.86. The aw for mold and yeast growth is about 0.61 with the lower limit for the growth of mycotoxigenic molds at 0.78 aw.

Measuring aw in Food

Water activity can be measured using a water activity meter. The required amount of sample is placed in a water activity sample vessel and is brought to ambient temperature. The sample is then placed within the airtight measuring cell of a calibrated water activity meter. Once the atmosphere within the cell has equilibrated, and the digital read-out has stabilized, the aw value can be recorded.

Precise control of temperature is very important when taking measurements. The equipment should be calibrated at the same temperature that is used for analyzing the samples. The sample to be measured should be uniform. 

Potchara Sungtong Director, Business Development

Food & Beverage Technology

DKSH Management (Thailand) Limited

potchara.s@dksh.com 063 858 6581

Author info พชร สังข์ทอง

Indena’s Quercefit® is an innovative 100% food-grade delivery system of quercetin based on Phytosome® technology, which optimizes quercetin bioavailability (up to 20 times and in the range of a diet rich in vegetables and fruits) with dose linearity. It has been proven to be an effective natural help to manage early stage conditions of COVID-19, in combination with standard care.

Although the emergency due to the pandemic is luckily decreasing at a global level, COVID-19 continues to be the focus for several scientific analysis. Quercetin Phytosome® has been the object of several human studies in the last two years - the most recent one issued in January 2023 - which demonstrated that this ingredient, in combination with standard care, when used in early stage of COVID-19, could aid in ameliorating the early conditions and helps keeping the immune system strong, mildening the symptoms and optimizing the timing of molecular test conversion from positive to negative.

The most recent study involved a larger group of subjects (100 subjects consisting of 50 people in the quercetin group and 50 ones in the control group) completing the preliminary data anticipated and published in 2021.

Antonella Riva, Head of Product Innovation and Development & LCM of Indena S.p.A, commenting the study “Quercetin as a possible

complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial” by Di Pierro et al., explains: “This randomized clinical trial investigated the possible adjuvant effect of an oral quercetin supplementation in mild to moderately symptomatic COVID-19 outpatients. The results revealed that subjects who received quercetin in addition to standard care, cleared the virus better (tested negative for SARS-CoV-2) and had milder symptoms as compared to the people who received the standard care alone. Moreover, participants in the quercetin group also showed statistically significant improvement in the serum levels of inflammatory biomarker LDH. Also the outcomes of our last study then - adds Riva - suggest possible quercetin supplementation effectiveness in the early-stage mild to moderately symptomatic COVID-19 outpatients and may help in optimizing the clearance of the SARS-CoV2 infection, mildening of the symptoms and modulation/control of the host’s inflammatory response. The study also supports the safety of quercetin supplementation in subjects with COVID-19 which has an unpredictable and complex course and hence may be potentially used as an adjuvant alongside routine care in the management of mild to moderate symptoms of COVID-19”.

"We keep devoting resources to clinical research with the aim to get stronger and stronger scientific evidences about

Indena’s ingredients. We’re very happy and proud to see such results from our Quercefit® and to give our contribution in helping people’s health which has had to face one of the most serious pandemics in recent years” adds Stefano Togni, Chief Commercial Officer of Indena S.p.A. Quercetin, a flavonol not naturally present in the human body, is the most abundant polyphenol in fruits and vegetable and is widely used as a dietary supplement to boost the immune system and in general to promote a healthy condition. Quercetin is characterized by crucial pharmacological properties including, antioxidant and immune-protective effects, which allows it to be a potential candidate to support all unpleasant conditions where oxidative stress, inflammation and immunity are involved. These conditions include discomforts related to cardiovascular health, healthy-aging, bones and joint health, sport and physical activity, gut and respiratory health.

Quercefit® is Indena’s formulation of quercetin deriving from the flower buds of Sophora japonica L., based on Phytosome® proprietary technology that optimizes its biological absorption. It has been proven that Quercefit® is able to modulate biological markers, typical in inflammatory conditions, in respiratory health, endurance and eye health and that it is an effective support for healthy aging thanks to its senolytic action. That is why Quercefit® may be called a multitarget product, which can be of help for several conditions. 

ทางชีวภาพ ได้ถ่ายทอดเทคโนโลยีการ

โพรไบโอติกส์สำาหรับระบบทางเดินอาหาร” ให้แก่ บริษัท อินโนบิก (เอเซีย) จำากัด ใน เครือบริษัท ปตท. จำากัด (มหาชน) ซึ่ง เป็นผลสำาเร็จจากการคัดเลือกเชื้อโพรไบ โอติกส์สายพันธุ์ไทยที่พัฒนาโดยนักวิจัย ไทยเป็นครั้งแรก เพื่อให้เหมาะกับคน

ไทย ภายใต้บันทึกความเข้าใจขับเคลื่อน

นโยบายเศรษฐกิจ BCG เพื่อนำาผลงาน

วิจัยวิทยาศาสตร์ เทคโนโลยีและนวัตกรรม

ด้านเทคโนโลยีชีวภาพ เทคโนโลยีอาหาร

บ่มเพาะธุรกิจไปใช้ประโยชน์สู่เชิงพาณิชย์

probiotic dietary supplements for digestive system

(ICPIM)

Innovative Center for Production of Industrially Used Microorganisms

brc@tistr.or.th 061 414 3934, 0 2577 9771

ประโยชน์จากความหลากหลายทางชีวภาพ ตามนโยบาย BCG จะก่อให้เกิดประโยชน์ สูงสุดกับหน่วยงานและผู้เกี่ยวข้องทุกฝ่าย ทั้งในระดับนโยบายและระดับปฏิบัติ เป็น ตัวอย่างของการบูรณาการความร่วมมือ กันระหว่างหน่วยงานภาครัฐ อีกทั้งยังส่ง ผลการวิจัยและพัฒนาด้านวิทยาศาสตร์ เทคโนโลยี

ในอุตสาหกรรมอาหาร มีโครงสร้างพื้นฐาน สำาหรับงานวิจัยพัฒนาตั้งแต่ระดับต้นทาง

ฐาน บริษัท ปตท. จำากัด (มหาชน) และ ประธานกรรมการ บริษัท อินโนบิก (เอเซีย) จำากัด กล่าวว่า อินโนบิก (เอเซีย) เติบโต

อย่างต่อเนื่องในระยะเวลา 2 ปีที่ผ่านมา

“Leading Life Science Company in Region by Bringing Best Science and Enhancing Quality of Life”

Ministry of Higher Education, Science, Research and Innovation (MHESI) by Thailand Institute of Scientific and Technological Research (TISTR) driving BCG economy model together with Innobic (Asia) Co., Ltd., a subsidiary of PTT Public Company Limited, launches “probiotic dietary supplements for digestive system” which helps balance your gut and boost your immune system under “Innobic Probiotics GD” brand, the nutritional product for the good quality of life of Thai people.

Prof. Chutima Eamchotehawalit, Ph.D., Governor of Thailand Institute of Scientific and Technological Research (TISTR) by ICPIM under the Biodiversity Research Centre conducts production technology transfer of “probiotic dietary supplements for digestive system” to Innobic (Asia)

Co., Ltd., a subsidiary of PTT Public Company Limited. The technology comes from successful selection of Thailand’s probiotic strain developed by Thai researchers under the MOU to drive economy through BCG policy and push research in science, technology, innovative biotechnology and food

technology output to commercial use. Presently, Innobic (Asia) Co., Ltd. starts producing the product named “Innobic Probiotics GD” which helps balancing the intestines and enhancing the immune system. One capsule contains Lactobacillus paracasei, Bifidobacterium breve,

Bacillus coagulans and Inulin. This is an important step of the operational integration to use Thailand’s probiotic strain which is a biodiversity that Thailand has an advantage. Currently, Thailand is stepping into a new industrial reform based on the potential and advantages of the country’s biodiversity.

“TISTR sets the policy to drive the BCG economy using the advantages of microorganisms in order to create business opportunities for entrepreneurs and drive local economy concerning agriculture, food, health food, medication, energy and environment. We aim to drive and extend the research and development output, create a spin-off in innovative business, and lay the country’s foundation for a bio-industry-driven mechanism. These will generate value creation and global competitiveness for Thai industry. TISTR will further cooperate with Innobic (Asia) Co., Ltd. and will focus on biodiversity advantages following the BCG policy. We believe that it will create the utmost benefit in both policy and operational levels for all departments and stakeholders. It is an example of the cooperation and integration between government agencies, and it will further the sustainability of the research and development in science, technology and innovation.”

The Governor of TISTR said.

The Innovative Center for Production of Industrially used microorganisms (ICPIM), TISTR, has the potential and readiness in research and development, innovation and manufacturing (RDIM). In addition, it is comprised of experienced researchers who are proficient in technology of probiotics and food microorganisms. ICPIM consists of the infrastructures for research and development from

upstream unit including specialized laboratory in laboratory level and animal level to clinical trial and downstream unit. Its production process meets international standard. It is accredited by the FDA and it is considered the country’s first complete production line for sustainable health benefits. It helps expanding food and health food industry, responding to technology changes, and increasing the competitiveness.

Dr. Buranin Rattanasombat, Chief New Business and Infrastructure Officer of PTT Public Company Limited, and Chairman of Innobic (Asia) Co., Ltd. said that Innobic (Asia) has grown continuously in the past 2 years from the commitment of its vision, “Leading Life Science Company in Region by Bringing Best Science and Enhancing Quality of Life”. Innobic (Asia) intends to become a leading life science company in the region and provides excellent science to improve the quality of life of the people. Today, the company is successful and recognized by partners and industry experts. Innobic (Asia) aims to serve the aging society and

healthcare in order to foster good health and promote the country to be the center of global health. To reduce import dependency and promote Thai research and researchers to the international level, Innobic (Asia) acts as a platform model that gathers the experts to create and drive the health business with concrete innovations and commercial products.

Innobic (Asia) has established Innobic Nutrition Co., Ltd. to conduct business in the field of medical nutrition for patients as well as nutraceuticals which it will penetrate the nutritional supplement market and focus on individual groups based on age, gender or nutritional needs to prevent various diseases and balance human’s life. It will expand to food products for patients and dietary supplements in the future. The Innobic Probiotics GD product is now available at all Lab Pharmacy shop and leading pharmacies nationwide, as well as at Innobic Official Shop on Shopee online platform. 

SYNERGY FLAVOURS INNOVATES

CUISINE PAIRINGS FOR LOW-AND NO-ALCOHOL BEVERAGES

Anna Marsden-Walker, Junior Account Executive The Scott Partnership Ltd amw@scottpr.com

ได้สร้างสรรค์การจิบเครื่องดื่มกับอาหารของน้ำาอัดลมระดับพรีเมียมและเครื่องดื่มปราศจาก

ธุรกิจยุโรปอาวุโสของซินเนอร์ยี่ ฟเลเวอร์ ส ให้ความเห็นว่า

พิถีพิถันและการจับคู่รสชาติของน้ำาอัดลม สามารถกระตุ้นความสนใจแบบเดียวกันกับ อาหารที่เข้ากันได้ดีกับไวน์และเบียร์ จาก งานวิจัยของเราพบว่าผู้ใหญ่ 55% เลือก ดื่มน้ำาเปล่าหรือน้ำาโซดาคู่กับอาหารหลัก ดังนั้นจึงเป็นโอกาสดีในการดึงดูดความ

การจับคู่ที่เหมาะสม สร้างความน่าสนใจ ได้มากกว่าน้ำาเปล่า

ใช้น้ำามะพร้าวในเครื่องดื่มอาจให้รสเค็ม เล็กน้อยซึ่งช่วยเสริมมื้ออาหาร

Synergy Flavours has crafted flavour pairings for premium soft drinks and alcohol-free beverages that complement some of the UK’s favourite global cuisines, including Indian, Italian, Greek, British, Chinese, and Thai, to optimise dining experiences. The cuisine-paired profiles follow Synergy’s launch of botanical extracts in January 2022, targeted at the low- and no-alcohol category.

The new flavour combinations include a mango, lime, and mint blend, which complements the flavours typically found in Indian cuisine, and pineapple, coconut, and lemongrass, to work in harmony with the tastes of Thai dishes. Other perfectly paired creations include; Sicilian lemon and bergamot to pair with Italian cuisine; salted cherry and ginger to compliment Chinese cuisine; plum, orange and chilli which works in harmony with the British roast dinner and finally green tea, lemon and mint which can accompany Greek fare.

A Good Sense Research report commissioned by Synergy found a staggering 87% of respondents commented that they were interested in purchasing a soft drink which would pair with their chosen cuisine. This demonstrates a clear need and opportunity for both soft drinks and non-alcoholic beverages to add value with more exciting options for mindful consumers. There is the opportunity to create balanced and refreshing drinks with optimised pairings that are more interesting than water, but pair better than a sweet cola or lemonade.

The low- and no-alcohol market is predicted to grow by 67% to £286 million by 2026 (Mintel), and with 49% of UK adults reporting to not drink any alcohol, or planning to reduce intake, this translates to 25 million potential consumers of lowand no-alcohol or premium soft drinks (Club Soda). The beverage market

is therefore primed for innovation, to diversify and enhance options for consumers who are looking for an alternative to alcohol.

Vicky Berry, Senior European Business Development Manager, Synergy Flavours commented, “Carefully crafted and paired flavours in soft drinks can encourage the same attention to cuisine compatibility that is well established in wine and has become commonplace in beer. We have seen from our commissioned research that 55% of adults choose water or sparkling water with a main – so there is a real opportunity to capture the attention of the water drinker with more interesting beverages which taste nice on their own, while also enhancing the taste of a dish. We take inspiration from other beverage categories as well –for example, alcoholic beverages or tonics. In mixers, we are seeing more herbs and spices appear including lemongrass, basil, and peppercorn.”

Flavour research analyst, Charlotte Spitzner, Synergy Flavours, explains, “We approach developing flavours which pair with cuisines by exploring key aroma compounds in a specific cuisine, using a combination of in-house analysis and extraction techniques, alongside our research platforms and databases.”

Food items that share flavour compounds have the potential to pair well with each other and improve the overall sensory experience of

the consumer. After investigating possible pairings informed by science, Research Analysts then work with application and flavour development teams to create the best performing flavour combinations for the specific food item. As an example, to pair with the UK’s favourite global cuisine, Indian, Synergy developed a pairing of mango, lime and mint. The mango pairs with Citronellol (key compound in pepper) while lime compliments Cuminaldehyde (cumin) and Eucalyptol (pepper). Refreshing notes of mint do not only scientifically pair with Indian cuisine but also help to cut through the rich body of some Indian dishes. For Thai cuisine, Synergy paired pineapple, coconut, and lemongrass as a compliment to prominent Neral (lemongrass), Cuminaldehyde (cumin) and Aldehyde C18 (coconut).

According to Synergy, the entirety of the drinking experience should be considered when innovating with cuisine-paired beverages – using coconut water for example within a beverage can deliver a slight savourysalt taste which compliments a meal. Balancing sugar and acidity can also help to create a beverage that delivers an optimised experience when consumed alongside food. 

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report

Catherine Daniel Director External Communications, Life Sciences & Healthcare newsroom@clarivate.com

คลาริเวทระบุชื่อยาสิบห้าชนิดที่น่าจะมียอดจำาหน่ายสูงกว่าหนึ่งพันล้านดอลลาร์สหรัฐในรายงานยาที่น่าจับตา

รายงานเน้นไปที่การรักษาและให้ยาในปริมาณที่เหมาะสมแก่ผู้ป่วยแต่ละบุคคล

ขึ้นสำาหรับโรคหายากและเงื่อนไขที่ไม่สามารถรักษาได้ก่อนหน้านี้ การพัฒนาการรักษาที่สร้างความหวังจะเกิดขึ้นในไม่ช้า

FDA

เจ็ดปีที่ผ่านมา การเพิ่มขึ้นของยาเฉพาะ บุคคลส่งผลให้ประสบความสำาเร็จในส่วน ของเนื้องอกและโรคที่หายาก และอำานวย ความสะดวกในการบำาบัดสำาหรับสภาพที่ ไม่สามารถรักษาได้ก่อนหน้านี้

กับยาที่มีศักยภาพในการเปลี่ยนแปลง กระบวนทัศน์การรักษาและตอบสนองความ ต้องการของผู้ป่วยที่ยังไม่ได้รับการตอบ สนอง รายงานทำาหน้าที่เป็นแหล่งข้อมูล อุตสาหกรรมที่สำาคัญในภูมิทัศน์นวัตกรรม

รายงานยังเน้นยาที่ได้รับความนิยมสูง ในจีนแผ่นดินใหญ่อีกด้วย คลาริเวทระบุ ยาเก้ารายการที่มีแนวโน้มแตะหนึ่งพันล้าน ดอลลาร์สหรัฐภายในปี 2573 ทั้งผลิตใน ประเทศและผลิตทั่วโลก โดยพบว่าในเก้า รายการนั้นเป็นยารักษามะเร็งถึงแปดรายการ ซึ่งสะท้อนให้เห็นถึงการปฏิรูปด้านการดูแล สุขภาพภายใต้นโยบาย Healthy China 2030 ที่ให้ความสำาคัญกับการจัดการกับโรค

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions

Promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer on horizon

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch™ report. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. The report serves as a key industry resource in an ever-evolving drug innovation landscape - with more than 70 drugs having been identified as Drugs to Watch. This year’s analysis identifies drugs entering the market or launching key indications in 2023 which are predicted to achieve blockbuster status by 2027 or be clinical game changers for millions of patients worldwide. Clarivate analysts identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than

$1 billion within five years. These promising advancements include a broad spectrum of therapeutic developments for rare diseases and tough-to-treat conditions, including HIV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer.

The Drugs to Watch 2023 list from Clarivate primarily features treatments targeted to a particular biomarker, ensuring greater efficacy and less precious time lost searching for a drug or biologic that will arrest or reverse the progress of disease. Personalized medicines have begun to evolve from promise to reality, accounting for more than 25% of FDA approvals for the last seven years. The rise of personalized medicine has resulted in success beyond oncology and rare diseases, facilitating therapies for formerly untreatable conditions.

The report also highlights potential blockbusters in Mainland China. Clarivate identified nine drugs that are likely to achieve $1 billion in Mainland China by 2030, including both global and domestically manufactured assets. Of the nine selected, eight are oncology drugs, reflecting healthcare reforms under Healthy China 2030 that have placed a focus on addressing the increasing cancer burden in Mainland China.

In addition, the report examines the industry’s progress in addressing the diseases highlighted in the United Nations Sustainable Development Goals. These goals address infectious diseases such as tuberculosis, malaria, neglected tropical diseases and waterborne diseases, as well as maternal mortality and non-communicable diseases like mental illness and substance abuse.

Among new drugs and biologics that have either won approval or are poised to, Clarivate has identified 15 treatments likely to achieve blockbuster status in the next five years or transform paradigms to meet unmet patient needs. The 2023 Drugs to Watch, are:

Bimekizumab (BIMZELX®) developed by UCB- Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate to severe plaque psoriasis. Phase 3 trial results showed superior skin clearance outcomes than existing treatments. Its lessfrequent dosing schedule and good safety profile will likely be attractive to clinicians and patients.

Capivasertib (AZD5363) developed by AstraZeneca- For patients with breast cancer, Capivasertib is a novel, highly potent, selective ATPcompetitive pan-AKT kinase inhibitor that exerts similar activity against the three isoforms AKT1, AKT2 and AKT3. Positive data have emerged from early-phase trials, with clinical benefit to patients irrespective of their PIK3CA/AKT1/PTEN mutational status, and several phase 3 trials are now underway.

Daprodustat (GSK1278863/ Duvroq) developed by GSK plc.Daprodustat belongs to a novel class of oral treatments for chronic kidney disease (CKD)-related anemia and is a HIF-PHI developed to treat anemia associated with CKD, which has a high incidence rate and few effective, safe treatment options. Already available for CKD-related anemia in Japan, its uptake has been impressive.

Deucravacitinib (SOTYKTU™/ BMS-986165) developed by Bristol Myers Squibb- As a first-in-class oral, targeted agent that selectively inhibits tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member that mediates cytokine-driven immune and inflammatory signals, it has the potential to fill a gap in the treatment armamentarium for plaque psoriasis.

Foscarbidopa/foslevodopa (ABBV-951) developed by AbbVieFoscarbidopa/foslevodopa is a novel reformulation of the gold-standard

Parkinson’s disease treatment (carbidopa/levodopa) delivered via a subcutaneous pump for the treatment of motor fluctuations in advanced Parkinson’s disease. In addition to serving a niche group of patients with high unmet need, it offers better efficacy than orally administered carbidopa-levodopa, dosing flexibility and a more convenient pump than existing and upcoming competitors.

LEQEMBI™ (BAN2401) developed by Eisai Co Ltd and Biogen Inc, and Donanemab (LY3002813), developed by Eli Lilly and Company- LEQEMBI and Donanemab are poised to help treat early-stage Alzheimer’s disease. Supported by landmark clinical data from a phase 3 trial, next-inclass anti-Aβ monoclonal antibody (MAb) LEQEMBI has recently received accelerated approved by the U.S. and has ex-U.S. launches. Donanemab, and others in the class (e.g., Roche’s gantenerumab), may follow suit pending the results of ongoing trials.

Lenacapavir (Sunlenca®/GS6207) developed by Gilead Sciences Inc.- Approved in Europe and under evaluation by the U.S. Food and Drug Administration (FDA), lenacapavir is the first-in-class, long-acting HIV1 capsid inhibitor approved to treat multi-drug resistant (MDR) HIV in people who have been heavily treated, a patient population with unmet medical need. Also currently being investigated to treat HIV

and for pre-exposure prophylaxis (PrEP), its infrequent dosing and self-administration will likely make it a favored choice in a population with treatment adherence challenges.

Mirikizumab (LY-3074828) developed by Eli Lilly and Company -Mirikizumab, a monoclonal antibody targeting the p19 subunit of IL23, will likely be first-in-class for ulcerative colitis and the third in the class approved for Crohn’s disease. Part of a set of emerging therapies with novel mechanisms of action, it will contribute to the growing market share held by these therapies.

Pegcetacoplan (EMPAVELI®/ ASPAVELI®/APL-2) developed by Apellis Pharmaceuticals Inc.Pegcetacoplan has launched already in the United States and Europe for Paroxysmal nocturnal hemoglobinuria (PNH), a rare hematological disease. As one of the few drugs to have completed phase 3 trials for GA, pegcetacoplan is expected to be the first drug to launch for geographic atrophy (GA)or “dry late age-related macular degeneration (AMD),” which has no approved pharmacotherapy.

Ritlecitinib (PF-06651600) developed by Pfizer Inc.- Ritlecitinib will likely benefit from its first-inclass status, rapid onset of action and expected label for both adults and adolescents, potentially providing an effective option to stimulate hair growth in a stigmatizing diseaseAlopecia areata.

Article info

 The Personalized Medicine Coalition (PMC). PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021. 2021. https://www.personalizedmedicinecoalition.org/Userfiles/PMCCorporate/file/Personalized_Medicine_at_FDA_The_Scope_Significance_of_Progress_in_2021.pdf

 Peijie Chen, Fuzhong Li, Peter Harmer. Healthy China 2030: moving from blueprint to action with a new focus on public health. 2019. https://pubmed.ncbi.nlm.nih.gov/31493840/

Sparsentan developed by Travere Therapeutics Inc - Sparsentan is a first-in-class, orally active, single molecule that functions as a high-affinity, dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors, which are associated with progression of kidney disease. Its development for IgA nephropathy and focal segmental glomerulosclerosis (FSGS) promises to halt that progression for many patients and fills a gap in the treatment armamentarium.

Teclistamab (TECVAYLI®/ JNJ-64007957) developed by Janssen Pharmaceutical Companies of Johnson & Johnson - After receiving conditional approval from the EC (European Commission), teclistamab is the first-in-class bispecific antibody targeted to B-cell maturation antigen (BCMA) to treat multiple myeloma. Ongoing phase 3 trials are expected to provide confirmation of clinical benefit in teclistamab’s approved setting and lead to label expansions in other multiple myeloma patient populations, including in combination with other approved agents.

Teplizumab (TZIELD™/ PRV-031) developed by Provention Bio Inc- Teplizumab is the first immunotherapy to launch for T1DM and is a landmark drug given its potential ability to preserve beta cell function and delay the need for insulin treatment in those with type 1 diabetes mellitus (T1DM).

Valoctocogene roxaparvovec (ROCTAVIAN™/BMN-270) developed by BioMarin Pharmaceutical IncApproved by the European Commission (EC) in August 2022, valoctocogene roxaparvovec is also poised to be the

first gene therapy to launch in the United States for severe hemophilia

A. Treatment benefit is expected to last for years, reduce the number of bleeding events, minimize the need for replacement factor VIII (FVIII) and negate the use of otherwise burdensome prophylaxis treatment.

Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership, Clarivate: “While R&D productivity remained a challenge for pharma in 2022, the FDA only approved 37 NMEs during the year, we might expect the approval rate to recover in 2023 to pre-pandemic levels. While oncology remains a key focus for the industry, as the latest edition of Drugs to Watch shows, we can also expect to see approvals and launches for medicines in other disease areas.”

Despite the many urgent challenges life science companies will face in 2023, from patent cliffs to capital investment, the industry is on the cusp of unlocking revolutionary technologies that could greatly advance human health.

Methodology for the Clarivate Drugs to Watch 2023 Report

Increasingly, companies are targeting smaller patient populations with more targeted drugs, many of which will garner less revenue than the mass-market drugs that have traditionally formed the bread and butter of large pharmas but which stand to greatly advance patient care. Accordingly, Clarivate revised its methodology to recognize late-stage developmental therapeutics of clinical and commercial notes.

To identify this year’s Drugs to Watch, Clarivate drew from the

expertise of over 160 analysts covering hundreds of diseases, drugs and markets and eleven integrated data sets that span the R&D and commercialization lifecycle, including: Cortellis Competitive Intelligence™, Disease Landscape & Forecast, BioWorld™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Generics Intelligence™, Cortellis Deals Intelligence™, Access & Reimbursement payer studies, Clarivate Real World Data and Analytics, Web of ScienceTM , Derwent Innovation™ and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2022 were selected for analysis, including those pursuing new indications that could be particularly impactful; drugs launched prior to 2022 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2027. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors, and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic gamechangers. Please note that Clarivate analysts generated the data shown in this report prior to December 15, 2022. The Drugs to Watch 2023 Report and the treatments referenced in this release are based on Clarivate’s current expectations based on existing data, but actual results derived from the drugs named in the report and here may differ significantly. 

Meat Pro Asia: The Ultimate Destination for the Meat Processing and Packaging Industry

Saengtip Techapatiphandee

Marketing & Communications Manager, VNU Exhibitions Asia Pacific Co., Ltd. saengtip@vnuasiapacific.com +662 1116611 Ext. 330

ต้นทุนจากกระบวนการผลิตเพื่อเพิ่มมูลค่าให้กับธุรกิจจะเป็นปัจจัยสาคัญและดึงมูลค่าการผลิตให้สูงขึ้นในวงจรห่วง

เปิดเผยรายชื่อผู้ประกอบการที่จะมาร่วมจัดแสดงเทคโนโลยีและนวัตกรรมการผลิตสำาหรับกระบวนการแปรรูปชิ้นเนื้อ

100 รายจาก 20 ประเทศทั่วโลกพร้อมนำาเสนอเทคโนโลยีการ จัดการแบบครบวงจรตั้งแต่การแปรรูปชิ้นเนื้อจนถึงการเสิร์ฟอาหารบนโต๊ะอาหาร โดยครอบคลุมทุกแนวทางการ

คำาแนะนำาเพื่อการเพิ่มมูลค่าของสินค้าเพื่อให้เกิดความคุ้มค่าสูงสุด

“เป็นเรื่องน่ายินดีที่ได้เห็นรายชื่อผู้เข้าร่วม งานยืนยันการเข้าร่วมแสดงงานกับ

งาน Meat Pro Asia (มีท โปร เอเชีย) ที่พร้อมเปิดประตูต้อนรับทุกท่านในเดือนมีนาคมนี้

With global meat prices rising more than 10% in 2022, reliable processing methods and quality assurance are becoming vital pieces of the puzzle when it comes to reducing costs from wastage and extracting maximum value from the food processing chain. With the exhibitor lineup for next month’s inaugural edition of Meat Pro Asia now confirmed, it’s clear that these considerations will be at the top of the agenda in Bangkok from 8-10 March. The focus will be on how to deliver meat from farm to table in a cost effective and scalable way, with more than 100 exhibitors from 20 countries and regions participating

“It’s pleasing to see the exhibitor list take shape, and in particular the presence of suppliers with strong research and development backgrounds who are pushing the industry forward in areas such as food preservation and sample analysis; the building blocks of a safe and cost-effective food chain,” says Mr. Richard Li, Executive Director, Messe Frankfurt (HK) Ltd. “This has set the stage

for a productive fair in March, with exhibitors delivering plenty of value for the local market.”

Highlights of Meat Pro Asia include:

 100 leading companies from the top level of the meat and food processing industry showcasing their innovation and technology.

 30+ intensive conferences covering a range of topics, including Future Food, Food Safety, Halal, Sustainability, and a panel discussion on the future of meat processing trends and opportunities.

 A wide range of product highlights, including new product launches, demonstrations, and handson workshops.

 A free Guided Tour service to help visitors explore the fair and meet potential partners.

 A free shuttle service available for pre-booking in advance to make your visit to Meat Pro Asia 2023 even more convenient.

Sample analysis and preservation

While fuel inflation and the cost of grains fed to farmed animals are two of the main causes of increased meat prices, food wastage is also a consideration when it comes to keeping costs under control. Offering solutions to this issue, and

in recognition that rising affluence is driving more meat consumption in Southeast Asia, many European and Chinese brands have identified Meat Pro Asia as an opportunity to showcase their sample analysis and preservation solutions. Some of the most notable include:

 Bizerba, a German manufacturer of inspection systems for food production, will showcase their iMD pro metal detection system, complete with an integrated conveyor for reliable and flexible quality assurance.

 Qingdao Main-Link Cleaning Equipment, specializing in hygiene and food safety, will exhibit their Centralised Foam Wash & Sanitizing System, designed for use in food processing and abattoirs. HiperScan will demonstrate their quick and reliable examination technology for all types of meat products.

 Wuhan Grand Hoyo, a new manufacturer of food grade glycine, will showcase the preservation and seasoning properties of their product.

 Munforks, a Swedish brand, will present their SPS10 Carcass Splitting Blade, 4TPI Meat Bandsaw Blade, and Toothed Bacon Slicer.

 Rieckermann, a reliable service and technology provider, will showcase their customized, high-quality solutions for the whole value chain of industrial production.

 Mettler Toledo will offer solutions for laboratory analytical instruments, inline analytical instruments, and digital balances.

Held together with VIV Asia –the largest fair in Asia for livestock production and animal husbandry, Meat Pro Asia focuses exclusively on solutions that deliver meat from farm to table. This includes slaughtering, the full processing chain, packaging,

labelling, cold chain logistics, quality control, hygiene, IoT and automation, waste water treatment and more.

Topnotch of the Conference Program

The conference program at Meat Pro Asia 2023 is set to be the topnotch event in the animal protein production industry. With a lineup of expert speakers and interactive sessions, attendees will have the opportunity to learn from the best in the business. Some of the highlights of the conference program include:

 The Future Food Conference presented by Good Food Institute Asia Pacific, Bühler, Thai Union Group

 The Sustainable Food presented by Multivac Group, Mayekawa, Bizerba Southeast Asia, HiperScan

 The Food Safety presented by Ecolab, Mettler Toledo, Moba, Marel

 The Halal Food presented by LPPOM MUI, The Halal Science Center, Chulalongkorn University, Vikan A/S

 Trends, Challenges and Opportunities of Alternative Proteins in Asia, 10 March at 13.30-15.00 at VIV Square

Ms. Panadda Kongma, Director of Agribusiness and Operations, VNU Asia Pacific, adds: “Although Meat Pro Asia is a new fair and therefore still in its growth stage, we see strong potential for the first edition due to its co-location with VIV Asia – the largest trade fair from feed to food in the region. This guarantees a solid turnout of engaged buyers from the meat industry, and extensive crossover business opportunities.”

With its focus on innovation and efficiency, Meat Pro Asia is the must-attend event for anyone involved in the meat processing and packaging industry. Whether you’re a manufacturer, supplier, or end-user, you’ll find everything you need to stay ahead of the curve.

Save the date: Meat Pro Asia 2023, in colocation with VIV Asia from 8-10 March, Challenger 1, IMPACT, Bangkok. Pre-register now at www. meatpro-asia.com

The fair is organised by Messe Frankfurt (HK) Ltd and VNU Group. For more information, please email to meatproasia@ china.messefrankfurt.com and/or meatproasia@vnuasiapacific.com

French Pavilion

Takes Centre

Stage at VIV Asia 2023 with Cutting-Edge Livestock Industry Technologies

The French international development agency, will present 2 French pavilions at VIV Asia 2023, showcasing 50 companies at the IMPACT Exhibition and Convention Center from 8th to 10th March 2023. Hall 1 will feature breeding and genetics equipment, while Hall 3 will showcase food and animal health companies. The pavilion will fall under the “Choose France” banner.

With 50 participants spanning sectors such as automated farm equipment, genetics, animal health, and feed, French Innovation takes centre stage at VIV Asia 2023 through its two pavilions.

The event is a key exhibition for the companies interested in Southeast Asian markets, so much so that Business France offices in Vietnam and Malaysia are also working on inviting key buyers to meet with the French companies in Bangkok.

The country’s livestock sector solutions prioritize animal welfare, ecology, and efficiency, showcasing a strong commitment to innovation. France-Thailand’s “Year of Innovation 2023” will promote cross-disciplinary cooperations and new partnerships

between French and Thai institutions, academics, and industries.

Part of it will take place on March 9th, 2023, by Business France hosting a conference titled “A Dialogue Between French and Thai Innovations for the Sustainable Development of the Livestock Sector” from 4 pm to 4:45 pm in Room Jupiter 12 of the IMPACT Convention Center in Bangkok. Participation is free of charge upon registration for every VIV Asia’s attendee.

Top companies and products to discover at the French Pavilions

The French pavilion at VIV Asia 2023 is set to be a must-visit event for livestock industry professionals and animal health enthusiasts alike. New to 2023: 7 companies showcasing some of the most innovative and cutting-edge technologies, equipment, and products available in the market. Some of the notable exhibitors and their products to spot on VIV Asia 2023’s French pavilions include :

 Food and animal health

The French Pavilions will host a hyperspecialized company in the animal nutrition-health market, and a pioneer in the circular economy and biotechnologies. Additionally, another company will be exhibiting their innovative knowledge in the manufacturing process, which includes the cold granulation technique and bolus production. Moreover, an exciting product for eggshell quality, designed to have a short reactivity time for a curative approach, will also be on display at the exhibition.

With exports of 3 billion euros worth of animal

feed products in 2020, France ranks as the sixth-largest global exporter of these products. (Source: French Customs)

 Equipment for breeding and genetics

Visitors can expect to see a professional and user-friendly software designed for the feed industry, as well as a new RFID TAG that can read at a distance of over 5 meters and enable the management of animal groups, including counting and sorting. An exhibitor will present a unique 360° approach that guarantees reliable traceability, animal welfare, biosecurity, food safety, and environmental responsibility. Lastly, the exhibition will feature state-ofthe-art egg candling technologies, complete with robotic functionality, artificial vision, and new sexing technologies.

About our partners

The French Pavilions are supported by a regional partner agency in bringing companies together: Bretagne Commerce International (West of France).

The French Pavilions are organized in partnership with AIRFRANCE, the flag carrier of France headquartered in Tremblay-en-France. It is a subsidiary of the Air France–KLM Group and a founding member of the SkyTeam global airline alliance. 

PCHi 2023 Extends Warm

PCHi 2023 งานแสดงสินค้าอำานวยความสะดวกให้กับความต้องการในการสร้างเครือข่ายและการเรียนรู้แบบ เผชิญหน้า งานแสดงสินค้าด้านส่วนผสมเพื่อการดูแลบ้านและการดูแลส่วนบุคคล (PCHi) เป็นเวทีการจัดหาของจีน สำาหรับอุตสาหกรรมการดูแลส่วนบุคคลทั่วโลก เปิดงานแล้ววันนี้ในกวางโจวที่

เวทีทางเลือกสำาหรับการเปิดตัวสู่โลก ในครั้งนี้ งาน PCHi ฉลอง 15 ปีใน ฐานะเวทีของจีนที่ให้บริการด้านการค้นหา นวัตกรรมล่าสุดและส่วนผสมที่ดีที่สุดแก่ อุตสาหกรรม บริษัทจำานวนนับไม่ถ้วนไม่ ว่าจะเป็นบริษัทข้ามชาติหรือบริษัทของจีน ต่างเลือกเปิดตัวผลิตภัณฑ์ของตนเองที่งาน PCHi มาอย่างต่อเนื่อง

Shanghai JAKA Biotech นำาเสนอ ผลิตภัณฑ์ดูแลช่องปากล่าสุดของพวกเขา คือ Oralitos PE สารสกัดจากมะขามป้อมซึ่ง

สามารถดึงดูดนวัตกรรมชั้นยอดในแต่ละปี และเราต้องการก้าวไปข้างหน้าอย่างดีที่สุด ด้วยการแสดงสินค้าในงานนี้ จากที่ฉันเคย เห็นมา ผู้แสดงสินค้าล้วนทำาทุกวิถีทางเพื่อ สร้างความประทับใจแก่ผู้เข้าชมงาน และ ฉันดีใจที่เราก็ทำาเช่นกัน” Symrise เปิดตัวผลิตภัณฑ์ใหม่ที่งาน

เหมาะกับสูตรผลิตภัณฑ์ดูแลผิวและหนังศีรษะ โดยส่วนผสมกำาหนดเป้าหมายครอบคลุม มากยิ่งขึ้นเมื่อเทียบกับรุ่นก่อน ควบคุมทั้ง

ตัวรับ NK1 และ PAR2 และให้ผลต้าน

อาการคันที่ดีขึ้น Mr Calvin WANG เจ้า หน้าที่ฝ่ายการตลาดสำาหรับส่วนผสมเครื่อง สำาอางเปิดเผยว่า

วิทยาศาสตร์ที่เหมาะสมประกอบ สิ่งนี้ ผนวกกับความต้องการของเราในการเปิด ตัวที่งาน PCHi ซึ่งแม้แต่เพื่อนร่วมงาน ของเราทั่วโลกก็รู้ว่าเป็นงานอุตสาหกรรม ระดับแนวหน้าสำาหรับตลาดจีน การมาที่ งานนี้ทำาให้มั่นใจได้ว่าผลิตภัณฑ์หลักของ เราจะได้รับความสนใจอย่างที่ควรจะเป็น” เทรนด์ความงามและการคาดการณ์ ตลาด รี้ด ซิโนฟาร์ม เอ็กซิบิชั่นส์ (RSE) เผยแพร่ รายงานข้อมูลเชิงลึกพิเศษของอุตสาหกรรม (หรือที่รู้จักในชื่อ“Blue Book”) เป็นครั้ง แรกในปีนี้ ด้วยความร่วมมือกับมินเทล bevol.cn และ Beautydata.ai รายงานออกแบบมาเพื่อให้ตลาดใน ประเทศมีข้อมูลการวิจัยตลาดเชิงวิทยาศาสตร์

ปัจจุบันถือเป็นงานอุตสาหกรรม ประจำาปีที่ทรงอิทธิพลและอำานาจ ในปีนี้

ในหมวดผลิตภัณฑ์นวัตกรรมและบุคลากร สำาหรับความทุ่มเทของพวกเขาในการวิจัย และพัฒนาส่วนผสม คะแนนของผู้ได้รับการ เสนอชื่อมาจากบริษัทที่จัดแสดงสินค้าระหว่าง เดือนตุลาคมถึงธันวาคมปีที่แล้ว และผลงาน

ซึ่ง ได้แก่ ความช่างคิดของผลิตภัณฑ์ ความ เหนือกว่าทางเทคนิค และโอกาสการนำา ไปใช้งานในตลาด คณะกรรมการตัดสิน 18 คนประกอบด้วยผู้เชี่ยวชาญอาวุโส จากมหาวิทยาลัยและสถาบันวิทยาศาสตร์

Expo Facilitates Unprecedented Demand for In-person Networking & Learning

Personal Care and Homecare Ingredients (PCHi), China’s choice sourcing platform for the global personal care industry, today opens in Guangzhou at The China Import and Export Fair Complex to much fanfare. Over the next three days, visitors can expect to connect with key players, learn from industry veterans, and explore the latest innovative ingredients and service offerings presented by more than 700 exhibitors from around 30 countries and territories.

Choice Platform for Global Launches

With this edition, PCHi celebrates 15 years of serving the industry as China’s definitive platform for uncovering the latest innovations and best ingredients. A countless number of companies — whether MNC or domestic player — have chosen to debut their products at PCHi over the years, and many have gone on to perform well in their markets of influence.

Shanghai JAKA Biotech is offering a sneak peek of their brand-new oral care product, Oralitos PE, a Phyllanthus Emblica plant extract

that targets halitosis. Sharing about her company’s decision to do a global soft launch at PCHi 2023, Ms May SHI, GM for Marketing Development, said, “The event has established itself as a reputable industry staple that attracts top-notch innovations each year, and we wanted to put our best foot forward with this showcase. From what I’ve seen so far, exhibitors are pulling out all stops to impress the visitors and I’m glad we did, too.”

Also launching a new product at PCHi 2023 today is Symrise, who unveiled its SymCalmin® PLUS, an anti-itch active ingredient that is suitable for skin care and scalp care formulations. The ingredient targets a greater coverage compared to its predecessor — regulating both NK1 and PAR2 receptors — and offers an enhanced antipruritic effect. Mr Calvin WANG, Marketing Executive for Cosmetic Ingredients, expressed, “Over our years of participation, we’ve noticed that visitor awareness has increased and the industry is demanding more high-tech solutions with proper scientific documentation. This ties in with our preference to focus launch efforts around PCHi — even our global colleagues know that it is a top-tier industry event for the Chinese market, and being here ensures that our key product gets the right attention it deserves.”

On Beauty Trends and Market Predictions

For the first time this year, Reed Sinopharm Exhibitions (RSE) is releasing a special industry insights report (also known as a “Blue Book”) in collaboration with Mintel, bevol. cn, and Beautydata.ai.

Designed to equip the domestic market with scientific, objective market research data, the report comprises an analysis of recent beauty trends and up-and-coming market predictions organized in three sections — general, anti-aging, and sensitive skin.

RSE envisions this report as a regular feature and the desire is to spark inspiration, spur industry development, and enable companies to capitalize on available opportunities for greater success.

Fountain Awards Winners: Earning the Industry’s Nod of Approval

Earlier tonight at the Industry Night Dinner held at Intercontinental Guangzhou Exhibition Center, the PCHi Fountain Awards 2023 were presented to deserving winners across the 14 product and personnel categories.

First introduced in 2017, the PCHi Fountain Awards was established to reward the industry and spur it towards advancing research capabilities and

developing cutting-edge technologies, and today, it is an influential and authoritative annual industry event.

This year, RSE processed scores of nominations from exhibiting companies for categories comprising innovative products and also individuals, for their contributions in ingredient research and development.

Scores of nominations flowed in from exhibiting companies between October and December last year, and entries were assessed against standardized criteria including product ingenuity, technical prowess, and market application prospects. The panel of 18 judges comprise senior experts from prestigious universities and scientific institutes, leading R&D figures from renowned organizations such as Shiseido, Beiersdorf, LG Household & Health Care, POLA Chemical Industries, Unilever, China Association Fragrance, Flavor and Cosmetic Industries (CAFFCI), as well as industry experts from PCHi’s Cosmetics Science & Technology Innovation Committee (CSTIC).

The next edition of PCHi will take place from 20-22 March 2024 in Shanghai, China.

For more information, please visit www.pchi-china.com/en, or connect with PCHi on social media. 

ผู้ได้รับรางวัล PCHi Fountain Awards 2023

The winners of PCHi Fountain Awards 2023 are:

Award Winners Products

Skin

Microbiome CRODA BB-BIONT™

Moisturizing / Hydrating Silab APIOSKIN®

UV Stabilizing Shanghai JAKA Biotech Co., Ltd. Solarepare® MB

Emulsifying / Stabilizing

Anti-pollution (e.g. PM2.5, Blue light)

Zhongshan Boshen Chemical Ltd. POEM DL-100

Lubrizol Management (Shanghai) Co., Ltd.

Xpozuki Biotech Ingredient

Green / Sustainable Gattefosse China EleVastin

Sensory Enhancing Sensient Technologies Corp. (China) Limited ALOE Surface Treatment

Acne / Allergy Alleviation

Anti-aging

Bloomage Biotechnology Corp., Ltd.

Hybloom™ Zinc Hyaluronate (HA-Zn)

Shen Zhen Winkey Bio & Tech Co., Ltd. Erasin0003

Zhejiang Xingyue Biotechnology Co., Ltd.

Shanghai Coachchem Technology Co., Ltd.

SILKFACTOR™ Silk Peptide

EffeMIX®-Cynthia

Whitening / Brightening

Shanghai Oli Enterprises Co., Ltd

OLI-2181AP Aqua Glabridin

Shenzhen Siyomicro Bio-Tech Co., Ltd. Siyomicro-ERGO®

Clariant Chemicals (China) Ltd. Rootness Awake

Shanghai Benco Industrial Co., Ltd.

EcoCeramide ENP

Skin Barrier Repair

Evonik Specialty Chemicals (Shanghai) Co., Ltd.

Zhina Biotechnology Technology Co., Ltd.

RHEASOME®  CeraBoost

Small Molecule

Oat β-Glucan

Hair Care / Scalp Care

Best Newcomer Award

Outstanding Individual of the Year

Bloomage Biotechnology Corp., Ltd.

Hyanutra™-RH Hair Nourishing Shield

Symrise China Holding Co., Ltd. Crinipan® PMC green

Ichimaru Pharcos Co., Ltd – Mr. Ryota TAKEUCHI

Dongguan Wilink Biological Technology Co., Ltd. –Mr. DUAN Zhigui

Symrise China Holding Co., Ltd – Ms. LIANG Yuwen

Shanghai JAKA Biotech Co., Ltd. – Ms. LU Yina

PepsiCo จับมือกับ Northern Bottling Company

Northern Bottling Company

Northern Bottling Company (NBC) บริษัทในเครือของ Haidri Beverages Group ที่เมืองเปศ

Northern Bottling Company

Sidel ขยายความเชี่ยวชาญท้องถิ่นใน

เป็น

PepsiCo และ NBC กำาลังมี

Sidel

พร้อมกับความสามารถเฉพาะตัวในการจัด วางผังสำาหรับสายการผลิตความเร็วสูงพร้อม

PEPSICO PARTNER NORTHERN BOTTLING COMPANY TRUSTS SIDEL TO INSTALL ITS HIGHESTSPEED COMPLETE PET LINE

With increasing demand forecast for soft drinks in Pakistan in 2023, PepsiCo partner Northern Bottling Company is relying on Sidel to install a high-volume, high-speed carbonated soft drinks (CSD) line.

Sidel is applying its leading packaging solutions expertise to create the new complete line for Haidri Beverages Group’s subsidiary, Northern Bottling Company (NBC), in the city of Peshawar. Northern Bottling Company is the market leader in beverages for Pakistan’s northern region and has been a successful PepsiCo franchise for over 25 years.

Offering a capacity of over 45,000 bottles per hour, the line represents a new era of innovative technologies, high efficiency and productivity in Pakistan’s beverage industry. The new line will help unlock further capacity for Northern Bottling Company, which itself has seen volume growth of 30% in the year 2021-2022. It will handle four bottle sizes and five recipes, producing PepsiCo beverages Pepsi, 7up, Mirinda, Pepsi Diet and Sting energy drink, in 300ml, 345ml 500ml and 1500ml formats.

Serving a dynamic market

Sidel is enlarging its local expertise in Pakistan, a dynamic market, where PepsiCo and NBC are playing a significant role.

“Sidel’s absolute commitment to service, along with their unique ability to optimise layout within a high-speed line equipped with cutting-edge technologies has impressed us. These were the key reasons that we have entrusted Sidel with our new investment,” says Ali Navaiz, Group Chief Operating Officer, Haidri Beverages Group.

“We are excited by this collaboration,” adds Vedat Guler, Sales Director Middle East, Sidel. “We’re dedicated to helping NBC achieve its commercial, sustainability and efficiency goals by adding value with our innovative bottle design, and lower energy and resources solutions.”

Sustainable production

Sidel’s complete line will help NBC save energy and resources. In fact, Sidel’s Combi is able to blow bottles using the lowest possible blowing pressure, and the air is recycled. It also offers water savings on bottle base cooling. The line is capable of running recycled PET (r-PET) bottles, and with Sidel’s patent StarLite bottle base, NBC and PepsiCo’s future sustainability goals will be met. The innovative StarLite bottle base optimises the quantity of PET per bottle, contributing to sustainability both by reducing the use of material and lowering emissions during transport.

Reduced Total Cost of Ownership

Sidel is confident of meeting NBC’s high-performance targets and expectations, knowing that its line engineering and technology, innovative solutions, resource efficiency and packaging design improvements, together with its local service and aftersales support, will add value and reduce the Total Cost of Ownership (TCO).

GIVAUDAN ACTIVE BEAUTY BOOSTS WELL-AGEING WITH LAUNCH OF SILIPHOS®

Introducing the botanical retinol challenger that outperforms bakuchiol Siliphos® is the best natural alternative to retinoids. Suitable for delicate skin, Siliphos® is extracted by green fractionation from milk thistle fruits and powered by Phytosome® technology. This new active ingredient outperforms the plant-based retinol alternative bakuchiol while offering benefits that challenge retinoid efficacy by reducing wrinkles without side effects. Natural cosmetic alternatives are increasingly demanded by consumers, including in a more natural version of retinol. According to our global CMI study, 77% of the consumers across 6 countries declared that they would be very interested in a natural version of retinol: enjoying the multiple skin benefits without worrying about the potential side effects, such as: redness, dryness and irritation.

Giada Maramaldi, Botanical Actives Category Manager for Active Beauty: “Siliphos® is the first natural alternative to retinoids and bakuchiol capable of providing well-ageing benefits comparable to retinol. Extracted from Silybum marianum Gaertn fruit, it acts directly on collagen production to provide a natural, safe and efficient skincare solution, suitable for even most delicate skins.”

The well-ageing performance of Siliphos® was tested in a clinical study on volunteers presenting crow’s feet and forehead wrinkles. All tests demonstrated Siliphos® to significantly outperform bakuchiol and act as efficiently as retinoids by reducing:

- Crow’s feet wrinkles by x2

- Overall facial wrinkles by x2.3

Number of forehead wrinkles by 21.2%

- Circumference of forehead wrinkles by 17.4%

- Redness by 22.9%

อินกริดิออน อินคอร์ปอเรทเต็ด (ตลาดหลักทรัพย์นิวยอร์ก: INGR) ผู้ให้

กลยุทธ์ดังกล่าวส่งผลให้อินกริดิออนมีความ สอดคล้องกับเป้าหมายการพัฒนาที่ยั่งยืนของ องค์การสหประชาชาติ รวมถึงมีการขับเคลื่อน นวัตกรรมอย่างต่อเนื่องสำาหรับความพยายาม

100% ผ่านโครงการมาตรฐาน การผลิตข้าวอย่างยั่งยืน (Sustainable Rice

Platform: SRP) ซึ่งเป็นความคิดริเริ่มของ ทั่วโลกที่จะมอบโครงการประกันโดยจับมือ กับเกษตรกร 500,000 ราย และส่งมอบข้าว เหนียวที่ผ่านการรับรอง ซึ่งใช้ในการทำาผงและ แป้งมันสำาปะหลังดิบของอินกริดิออน โครงการ SRP ช่วยลดการใช้น้ำา เพิ่มความปลอดภัยให้ กับชุมชนนอกจากนี้และบรรเทาความยากจนในระยะยาว

เน้นถึงศักยภาพของมันในการลดน้ำาตาลอย่าง ยั่งยืนอีกด้วย: • อินกริดิออนทำาการประเมินวัฏจักรชีวิต เพื่อประเมินผลกระทบต่อสิ่งแวดล้อมที่อาจเกิด ขึ้นซึ่งเกี่ยวข้องกับวงจรชีวิตของหญ้าหวานตั้งแต่ เกิดจนตาย การศึกษาที่เป็นกรรมสิทธิ์นี้วัดผล กระทบต่อสิ่งแวดล้อมของสารให้ความหวาน ที่ได้จากใบหญ้าหวานตั้งแต่การสกัด

ด้านสิ่งแวดล้อมซึ่งรวมถึงการเปลี่ยนแปลง

น้ำา และความต้องการพลังงานสะสม สิ่งที่ค้น พบแสดงให้เห็นว่าเทคโนโลยีการหมักและการ แปลงทางชีวภาพได้ปรับปรุงความยั่งยืนของ

เช่น

หมัก Reb M ช่วยลดผลกระทบด้านลบต่อ การเปลี่ยนแปลงสภาพภูมิอากาศได้ถึง 82% เมื่อเทียบกับน้ำาตาล ในขณะที่การแปลงทาง ชีวภาพ (bioconversion) ลดลง 50% “ลูกค้าของเราต้องการโซลูชันส่วนผสม แบบองค์รวมที่ยั่งยืน เพื่อตอบสนองความ

การวิจัยเกี่ยวกับหญ้าหวานยัง

INGREDION RESETTING THE MARKET FOR SUSTAINABLY SOURCED INGREDIENTS

By partnering with local farmers and sourcing products sustainably, Ingredion ensures it is advancing sustainable initiatives in the region for long-term growth.

Ingredion Incorporated (NYSE: INGR), a leading global provider of specialty ingredient solutions to the food and beverage manufacturing industry, is furthering its sustainability initiative in the Asia Pacific region. Under the 2030 All Life plan, which aims to bring together the potential of people, nature and technology to make all life better, the strategy allows Ingredion to further align with the United Nations Sustainable Development Goals while driving continuous innovation in our sustainability efforts.

Globally, the company is making rapid progress toward its key milestone of having 99 percent of all crops and 100 percent of the company’s Tier 1 crops (corn, tapioca, potato, stevia and pulses) to be sustainably sourced by 2025.

Regional initiatives

Ingredion’s latest investment in China, Shandong South production facility thrives on sustainable sourcing of non-GMO corn from local farmers. Shandong South uses advanced digital technologies and automation to produce corn-based native and modified starch products that maintain international quality standards and create winning textures for food and beverage manufacturers.

Furthermore, two recent product launches showcase how Ingredion’s innovation is helping to meet this goal:

• Next Generation Waxy Tapioca: Following 10 years of agricultural innovation, Ingredion unveiled a next generation waxy tapioca starch that addresses extreme food manufacturing requirements and supports sustainability trends. Ingredion leads the sustainability initiative through empowering local farmers, helping them develop environmentally sustainable practices that ensure the long-term production of next generation waxy tapioca. Our end-to-end process from crop to manufacturing are fully integrated in Thailand, mitigating shipping costs regionally and reducing the impact of transportation on the environment.

• Waxy Rice: Ingredion also sources almost 100% of its waxy rice through the Sustainable Rice Platform (SRP)—the first initiative globally to offer an assurance scheme by partnering with 500,000 farmers and offering certified waxy rice that is used to make Ingredion’s functional native starches and flours. The SRP reduces water usage, improves the security of communities and alleviates poverty in the long run.

Additionally, research into stevia also highlights its potential for sustainable sugar reduction:

• Ingredion conducted a life cycle assessment to quantify potential environmental impacts associated with the life cycle of a stevia from cradle to grave. The proprietary study measured the environmental impacts of sweeteners derived from stevia leaves from their extraction and processing to their distribution to consumers, using environmental indicators which includes climate change, land use, water scarcity and cumulative energy demand. The findings show fermentation and bioconversion technologies have significantly improved the sustainability of Reb M—i.e. fermented

Sugarcane Reb M production reduces negative climate change impact by 82% compared to sugar, while bioconversion shows a 50% reduction.

“Our customers need holistic, sustainable ingredient solutions to meet consumer and regulatory demands for greater transparency,” shared Rishan Pillay, vice president and general manager of ASEANI and ANZ, Ingredion. “Partnering with our farmers and sustainably sourcing our products in the region helps us not only to improve crop yield and quality, but also better manage the costs associated with supply chain, while giving our customers what they need with the right sustainability messaging.”

He added: “We are proud to be the first Farm Sustainability Assessment (FSA)certified sustainable tapioca producer in Thailand. To drive environmental and social impact in our agriculture supply chain, we use the Sustainable Agriculture Initiative Platform’s (SAI Platform) Farm Sustainability Assessment, which benchmarks performance against 90 global standards to identify the greatest needs of growers in specific geographic regions.”

With this data, Ingredion’s local agricultural teams develop programs with growers to drive continuous improvements in their operations.

Global initiative

By the end of 2022, the environmental and human impact of 50 Ingredion strategic growth platform ingredients will be made available to the industry via HowGood, a SaaS data platform with the world’s largest database on food and personal care product sustainability, to meet and surpass customer demands for sustainable ingredients. This partnership will deliver data transparency on Ingredion’s top products and new product innovations which, along with Ingredion’s goals of having 99 percent of its global supply of crops sustainably sourced by 2025, will provide customers with sustainable solutions that consumers prefer.

These new tools and products are the latest examples of Ingredion’s leadership in sustainably sourced ingredients. The holistic approach of transparent, third-party data sharing, new product innovations and market-specific sustainable agriculture practices deliver solutions today that will enable healthier people and a healthier planet in the future.

About THE COMPANY

Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2021 annual net sales of nearly $7 billion, the company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labs® innovation centers around the world and approximately 12,000 employees, the company cocreates with customers and fulfills its

purpose of bringing the potential of people, nature and technology together to make life better. Visit apac.ingredion. com for more information and the latest company news.

About THE SUSTAINABLE RICE PLATFORM (SRP)

The Sustainable Rice Platform (SRP) is a global multi-stakeholder alliance of over 90 institutional members, coconvened by the International Rice Research Institute (IRRI), the United Nations Environment Programme (UNEP) and GIZ. Now established as an independent not-for-profit member association, SRP works with partners from across the stakeholder spectrum to transform the global rice sector by improving smallholder livelihoods, reducing the social, environmental and climate footprint of rice production, and by offering the global rice market an assured supply of sustainably produced rice.

About HOWGOOD

HowGood is a SaaS data platform with the world’s largest database on food and personal care product sustainability. With more than 33,000 ingredients, chemicals and materials assessed, HowGood helps leading brands, retailers and restaurants improve their environmental and social impact. Through in-depth, ingredient-level insights into factors like greenhouse gas emissions, biodiversity, labor risk, animal welfare and other key impacts, HowGood’s data powers strategic decision-making for the sourcing, manufacturing, merchandising and marketing of sustainable products.

News info

Ingredion - December 19, 2022

“เป็นเรื่องน่าตกใจที่ความหลากหลาย ทางชีวภาพในโลกของเรากำาลังลดลงอย่าง รวดเร็ว นั่นเป็นเหตุผลที่เรารู้สึกตื่นเต้น ที่ได้เพิ่มขีดความสามารถให้กับลูกค้าใน การสร้างผลิตภัณฑ์ที่รักษาความหลาก หลายทางชีวภาพ และในเวลาเดียวกันก็ สามารถส่งมอบการรักษาคุณภาพสูงแก่ผู้ ป่วย” Thomas Riermeier หัวหน้าสาย ธุรกิจดูแลสุขภาพของอิวอนิกกล่าว

Eur.) และไม่มีความเสี่ยงต่อการแพร่เชื้อ

โรค PhytoSquene® ยังเป็นวิธีแก้ปัญหา

สำาหรับผู้ป่วยที่ไม่สามารถใช้ผลิตภัณฑ์จาก

สัตว์ด้วยเหตุผลทางวัฒนธรรมหรือศาสนา PhytoSquene ® เป็นนวัตกรรม ล่าสุดของอิวอนิกเพื่อมอบโซลูชันที่ไม่ได้ มาจากสัตว์และมีความยั่งยืนให้แก่ตลาด โดยเมื่อต้นปีที่ผ่านมา อิวอนิกมีการเปิด ตัว PhytoChol® ซึ่งเป็นคอเลสเตอรอล เกรดยาที่ได้จากพืช

สควาลีนเป็นสารประกอบอินทรีย์ตาม ธรรมชาติซึ่งใช้เป็นส่วนประกอบในการ

สารเติมแต่งที่กระตุ้นการตอบสนองของ ภูมิคุ้มกันของร่างกายต่อสารออกฤทธิ์ ในวัคซีน ช่วยลดปริมาณสารออกฤทธิ์ที่ ต้องใช้ จึงทำาให้ผลิตวัคซีนเพิ่มได้เร็วขึ้น

in parenteral dosage forms. It meets the demand for a secure commercial supply of non-animal-derived squalene. Non-GMP samples of PhytoSquene® are available immediately with GMP quality to follow in 2023.

With the launch of PhytoSquene®, Evonik offers an alternative to animal-derived squalene, which for pharmaceutical applications is typically sourced from shark liver oil. Preserving biodiversity and ecosystems by reducing the need for animal-derived products is an important focus for Evonik and its life sciences division, Nutrition & Care.

Nutrition & Care has formulated a clear vision to transform more than 70 percent of its portfolio in terms of revenue to next-generation solutions by 2032. Next-generation solutions are based on a thorough portfolio assessment and represent a superior sustainability benefit.

PhytoSquene® is also a solution for patients who cannot use animalderived products for cultural or religious reasons.

PhytoSquene® is the latest of Evonik’s innovations to provide the market with sustainable, non-animalderived solutions. Earlier this year, Evonik launched the pharma-grade, plant-derived cholesterol PhytoChol®.

Squalene is a natural organic compound that is used as a component in some adjuvant systems. Adjuvants are additives that boost the body’s immune response to the active ingredient in a vaccine. They reduce the amount of active ingredient needed, thus making it faster and easier to scale vaccine production, and reducing the chance of any side effects in patients.

EVONIK LAUNCHES PLANTBASED SQUALENE TO BOOST VACCINE EFFICACY

 Sustainable alternative to squalene extracted from shark liver oil

 Adjuvant component for parenteral drug delivery applications

Increases share of next-generation solutions at Evonik

Evonik has launched a nonanimal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene® is the first known amaranth oil-derived squalene on the market for use in adjuvants

“It is alarming that biodiversity across our planet is declining at a rapid rate. That’s why we are excited about empowering our customers to create products that preserve biodiversity and, at the same time, deliver high-quality treatments to patients,” said Thomas Riermeier, head of the Health Care business line at Evonik.

PhytoSquene ® is made from the oil of amaranth (Amaranthus caudatus) which is an herbaceous plant cultivated in many parts of the world. Being plant derived, PhytoSquene® ensures batch-to-batch consistency, quality and purity. It is compliant with European Pharmacopoeia (Ph. Eur.) specifications and there is no risk of pathogenic transmission.

As a partner to the pharmaceutical industry, Evonik Health Care has been a leader in advanced drug delivery for decades. It supports pharmaceutical companies worldwide with comprehensive services for developing and manufacturing complex parenteral and oral drug products. This includes pharmaceutical excipients such as polymers and lipids, formulation development and the manufacture of clinical samples, as well as commercial drug products.

ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA

2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION

Ascelia Pharma AB (publ) – a biopharmaceutical company focused on improving the life of people living with rare cancer conditions – is presenting results from its Orviglance* Food Effect study at the RSNA conference 2022 (Radiological Society of North America – 27 November – 1 December Chicago, Illinois). The study evaluates the effect of food intake on the absorption and signal intensity of Orviglance, a manganese-based MRI contrast agent, and successfully concludes that image enhancement is not impacted by a light meal.

The Food Effect Study evaluates the effect of food intake on absorption and signal intensity of Orviglance, Ascelia Pharma’s investigational magnetic resonance-imaging (MRI) agent used in the visualization and detection of cancer in the liver in patients with reduced kidney function. The results show that intake of a light meal within 30 min prior to Orviglance administration provides similar image MRI enhancement of the liver compared to a fasting condition. In line with previous studies, the data also confirms strong image enhancement of the liver after Orviglance administration compared to an MRI image without a contrast agent. In clinical practice, the results demonstrate the possibility of being administered Orviglance both after fasting or after consumption of a light meal.

In this crossover study, Orviglance was administered to 24 healthy volunteers in fasting condition and in one of two conditions with food

intake (either a light or full meal). The image enhancement effect was measured by the change in the MR signal intensity before and after (1, 4, 8 and 24 hours) administration of Orviglance. The results showed that a light meal prior to Orviglance administration provided similar image enhancement when compared to a fasting condition, whereas the image enhancement was less pronounced for the group receiving a full meal. Ascelia Pharma has filed a patent application based on the results of the study.

The reporting of these final results for the Food Effect Study completes two of the three studies in Ascelia Pharma’s ongoing Phase 3 clinical program for registration of Orviglance. A Hepatic Impairment Study successfully concluded that Orviglance is well tolerated in patients with liver (hepatic) impairment, with only mild to moderate transient, gastrointestinal adverse events reported, such as nausea. No new safety concerns were identified. The data confirmed there was no renal excretion of Orviglance, and that excretion is primarily occurring via the liver also in this subgroup of patients.

The plan for the ongoing Phase 3 study, SPARKLE, required for a subsequent regulatory submission, is to complete patient enrolment by the end of this year. Data from all three studies will be included in the marketing authorization application to health authorities, including FDA and EMA.

Magnus Corfitzen, CEO at Ascelia Pharma, said: “We are very pleased to be presenting the study as an oral presentation at the RSNA. The possibility for omitting a fasting condition improves the convenience for patients and eases the administration of Orviglance in

clinical practice. The study provides robust evidence of the diagnostic value that Orviglance can offer once it is available to patients and physicians. Orviglance is being developed to address the unmet medical need of patients with poor kidney function who require liver imaging, and it is very encouraging that the study results support previous findings on the ability of Orviglance to provide strong image enhancement to liver MRI scans.”

Orviglance is a novel manganesebased oral contrast agent for MRI developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious, and potentially fatal, side effects from the currently available class of gadolinium-based contrast agents, which all carry black box warnings issued by regulatory authorities, such as the US Food and Drug Administration (FDA) because of this risk. Orviglance, which has been granted an Orphan Drug Designation by the FDA, is currently in Phase 3 development.

SPARKLE is a global multicenter study of Orviglance in up to 200 patients with severe renal impairment and known or suspected focal liver lesions. Primary efficacy, in terms of lesion visualization compared to unenhanced MRI (MRI without a contrast agent), will be evaluated by three independent blinded readers.

The Orviglance Food Effect study will be presented by Dr. Kohkan Shamsi at the RSNA on Wednesday, 30 November 2022 at 3,00pm ET. RSNA is the annual meeting of the radiologists, where new technologies and key research studies are presented. Visitors can attend in person, or virtually.

DOW FEATURES SEVEN NEW HIGH-PERFORMING AND SUSTAINABLE TECHNOLOGIES AT IN-COSMETICS ASIA 2022

Dow showcased seven high performing and sustainable new technologies to expand its personal care portfolio at in-cosmetics Asia 2022, taking place in Bangkok, Thailand on November 1st - 3rd at booth K30. Moreover, the team will display a series of innovative and inspiring formulations that will help brand owners to meet the growing demand for more sustainable cosmetic ingredients.

Scientific and marketing experts shared their scientific know-how, consumer knowledge and regulatory expertise and visitors are invited to discover the unique performance of Dow’s offering – one of the broadest portfolios in the personal care industry.

“Dow’s products featured in in-cosmetics Asia are uniquely developed and aligned with the latest beauty trends in the region,” said Isabel Almiro do Vale, Global Strategic Market Director of Dow Personal Care. “The ingredients being introduced today provide superior and multi-functional benefits across both hair and skin care formulations while delivering on consumer demands for affordable products that are safe for humans and the environment.”

CD-1 Polymer: A highly effective bio-derived and renewable deposition aid that boost a shampoo´s conditioning effectiveness using silicones or natural oils as benefit agent.

MaizeCare™ Clarity Polymer: The unique corn-based ingredient enables the creation of crystal-clear hair styling formulations while offering versatility from low to high hair fixation, consistent curl retention, and new and desirable compatibility with carbomer. Furthermore, it has a good potential as a transparent film former for cosmetic applications.

EcoSmooth™ Rice Husk Cosmetic Powder: Upcycled from non-GMO natural sources, the white silica powder delivers a unique sensorial experience and optical benefits like blurring imperfections. A must add to many common skincare, color cosmetics, and hair care formulations.

EcoSmooth™ Universal Fluid 1100: A new biodegradable and biobased carrier fluid suitable for color cosmetics, skincare, hair care, and deodorant applications. The innovation of this material combines its effectiveness in formulations as well as its unique production process which includes upcycled waste after crop harvesting. By combining performance and greener process Dow creates double value for people and planet

EcoSense™ GL-60 HL Surfactant and EcoSense™ GL-60 HA Surfactant: The two naturally derived (>99% bio-derived) bio-surfactants with emulsifying properties enable the creation of highly desirable mild cleansing products. Shampoo, face wash, body wash, and leave-on products like body lotion can feel even more comfortable on the skin and scalp. EcoSense™ GL-60 HL/HA Surfactants are non-GMO, sugar based and exhibits >60% biodegradation within 28 days per OECD 301F. An excellent fit to minimize environmental impact, allowing naturally derived formulations creation without compromise on performance.

DOWSIL™ 979 Emulsion: Developed with a sustainable focus, low cyclics content, and lower ecotoxicity than many of the emulsions containing quaternary-based surfactants, this product delivers the high-performance benefits, like reduced friction, enhanced dry or wet combing and restored hydrophobicity, as well as color protection and reduced hair breakage in conditioners, leave-in, and shampoo formats.

“The beauty and personal care industry are anticipated to rebound, and Asia Pacific remains as the exciting growth region. We are excited to launch seven new high-performing and sustainable technologies that will help our customers to create the next generation differentiating products that improve everyday living while sustaining the environment.” said Cedric Toh, Global Segment Leader and Regional Marketing Manager for Dow Personal Care. “We are committed to deliver a sustainable future for the world by connecting and collaborating with our partners to find new options for materials that make life better for everyone.”

At the booth, customers could discover the new ECOllaboration Concepts Collection and Natural Cosmetics Collection, which focused on the three key pillars of natural beauty: ecology, economic development, and eco-conscious mindset. These collections could inspire brand owners to create personal care solutions with outstanding performance that achieve a minimum natural origin content of 90% and are both inclusive and safe for people and the planet.

Your subscription

Fill out your detail or attach your business card

jatuporn.suttinak@